



Published in final edited form as:

Cell Rep. 2021 October 19; 37(3): 109834. doi:10.1016/j.celrep.2021.109834.

ROR and RYK extracellular region structures suggest that receptor tyrosine kinases have distinct WNT-recognition modes

Fumin Shi^{1,2,10}, Jeannine M. Mendrola^{1,11}, Joshua B. Sheetz^{3,4}, Neo Wu^{1,2,12}, Anselm Sommer^{3,4}, Kelsey F. Speer^{5,6,13}, Jasprina N. Noordermeer^{7,14}, Zhong-Yuan Kan^{1,15}, Kay Perry⁹, S. Walter Englander^{1,2}, Steven E. Stayrook^{1,3,4}, Lee G. Fradkin^{7,8,16}, Mark A. Lemmon^{1,2,3,4,5,17,*}

¹Department of Biochemistry and Biophysics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.

²Graduate Group in Biochemistry and Molecular Biophysics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.

³Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06510, USA.

⁴Yale Cancer Biology Institute, Yale University West Campus, West Haven, CT 06516, USA.

⁵Cell and Molecular Biology Graduate Group, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA

⁶Department of Medicine (Hematology-Oncology), University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA

⁷Molecular Cell Biology, Leiden University Medical Center, Leiden 2333 ZC, The Netherlands

⁸Department of Neurobiology, University of Massachusetts Medical School, Worcester, MA 01655, USA

⁹NE-CAT, Department of Chemistry and Chemical Biology, Cornell University, Argonne National Laboratory, Argonne, IL 60439, USA

¹⁰Present address: Cooley, LLP, Washington, DC 20004, USA

¹¹Present address: PTC Therapeutics Inc., South Plainfield, NJ 07080, USA

¹²Present address: Google Research, Mountain View, CA 94043, USA

¹³Present address: Department of Biology, University of Pennsylvania, Philadelphia, PA 19104, USA

*Correspondence: mark.lemmon@yale.edu (M.A.L.).

AUTHOR CONTRIBUTIONS

F.S., J.M.M., L.G.F., and M.A.L. designed the overall project. F.S., J.M.M., Z.W., and A.S. performed protein expression. F.S., J.M.M., K.H.P., and S.E.S. carried out crystallographic studies. J.M.M. and S.E.S. performed SAXS studies. Z.W. and F.S. performed HDX-MS – guided by S.W.E. and Z.-Y.K. – and J.B.S. assisted with analysis. F.S., J.M.M., A.S., and J.B.S. performed in vitro pull-down studies, and F.S., J.M.M., and K.F.S. undertook SPR experiments. L.G.F. and J.N.N. carried out in vivo experiments. M.A.L., F.S., and J.B.S. wrote the manuscript. All authors contributed to analysis of results and editing of the manuscript.

SUPPLEMENTAL INFORMATION

Supplemental information includes 6 figures and can be found in the online version of this article.

DECLARATION OF INTERESTS

The authors declare no competing interests.

¹⁴Present address: Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Palo Alto, CA 94305, USA

¹⁵Present address: GlaxoSmithKline, Collegeville, PA 19426, USA

¹⁶Present address: Department of Bioengineering, Stanford University, Palo Alto, CA 94305, USA.

¹⁷Lead Contact

SUMMARY

WNTs play key roles in development and disease, signaling through Frizzled (FZD) seven-pass transmembrane receptors and numerous co-receptors including ROR and RYK family receptor tyrosine kinases (RTKs). We describe crystal structures and WNT-binding characteristics of extracellular regions from the *Drosophila* ROR and RYK orthologs Nrk (neurospecific receptor tyrosine kinase) and Derailed-2 (Drl-2), which bind WNTs through a FZD-related cysteine-rich domain (CRD) and WNT-inhibitory factor (WIF) domain respectively. Our crystal structures suggest that neither Nrk nor Drl-2 can accommodate the acyl chain typically attached to WNTs. The Nrk CRD contains a deeply buried bound fatty acid, unlikely to be exchangeable. The Drl-2 WIF domain lacks the lipid-binding site seen in WIF-1. We also find that recombinant DWnt-5 can bind *Drosophila* ROR and RYK orthologs despite lacking an acyl chain. Alongside analyses of WNT/receptor interaction sites, our structures provide further insight into how WNTs may recruit RTK co-receptors into signaling complexes.

Keywords

WNT signaling; receptor tyrosine kinases; acylation; growth factor signaling; co-receptor; pseudokinases; ligand; receptor; cancer; *Drosophila*

INTRODUCTION

WNTs play diverse roles in development, adult stem cell renewal and tissue homeostasis (Nusse and Clevers, 2017), and are represented in humans by 19 different genes with different functions (Miller, 2012). Given their roles in many developmental processes and numerous diseases – from cancer to developmental defects to degenerative diseases (Nusse and Clevers, 2017) – there is a great deal of interest in understanding mechanisms of WNT signaling in order to develop approaches to modulate it therapeutically. The best known WNT receptors are Frizzleds (FZDs), members of the F class of G protein-coupled receptors (GPCRs) with a ~120 aa extracellular cysteine-rich domain (CRD) that directly binds WNTs (MacDonald and He, 2012). Details of WNT binding to the extracellular CRD of FZD₈ have been visualized crystallographically (Hirai et al., 2019; Janda et al., 2012), revealing as a key element accommodation of a WNT-associated acyl chain within a characteristic hydrophobic channel on the CRD surface. WNT acyl chain binding has been reported to promote dimerization of some FZDs (Hirai et al., 2019), which can be recapitulated when free fatty acids bind to isolated FZD CRDs (DeBruine et al., 2017; Nile and Hannoush, 2019; Nile et al., 2017). Other studies, however, suggest that WNT binding may dissociate FZD dimers (Petersen et al., 2017). Beyond possibly modulating FZD dimerization, WNTs

are thought to ‘bridge’ or cross-link FZDs to co-receptors such as LRP5/6 (Bourhis et al., 2010; Chu et al., 2013; Grumolato et al., 2010; Janda et al., 2017; Tao et al., 2019), and have also been reported to induce conformational changes in the FZD transmembrane region (Schihada et al., 2021; Wright et al., 2018).

Four of 20 families of human receptor tyrosine kinases (RTKs), which control many different cellular processes (Lemmon and Schlessinger, 2010), are now known also to be receptors or co-receptors for WNTs (Green et al., 2014; Niehrs, 2012; Roy et al., 2018). These are the ROR family (for receptor tyrosine kinase-like orphan receptor), RYK (for receptor tyrosine kinase-related tyrosine kinase), PTK7 (for protein tyrosine kinase-7), and MuSK (for muscle-specific receptor tyrosine kinase), which have all been shown to be involved in multiple aspects of WNT signaling (Fradkin et al., 2010; Green et al., 2008; Jing et al., 2009; Lhoumeau et al., 2011). Consistent with a role as direct WNT receptors, RORs and MuSK contain an extracellular CRD related to that seen in FZDs. RYK instead contains a WIF (for WNT-Inhibitory Factor) domain in its extracellular region, also implicating it in direct WNT binding (Hsieh et al., 1999). Interestingly, the RORs, RYK, and PTK7 stand out among RTKs by having pseudokinases in their intracellular regions (Mendrola et al., 2013; Sheetz et al., 2020). Thus, this group of WNT receptors is likely to differ from both FZDs and typical RTKs in their signaling mechanisms.

Given the importance of ligand-induced dimerization in regulation of most RTKs (Lemmon and Schlessinger, 2010), we were interested in understanding how WNTs engage ROR and RYK family members. We were also interested in assessing the importance of WNT acylation for ROR and RYK regulation, since sequence alignments suggest that ROR family CRDs do not maintain the hydrophobic channel seen in FZD CRDs (Janda and Garcia, 2015). Moreover, our previous studies suggest that WNT acylation is not always required for signaling (Speer et al., 2019). Here, we describe crystal structures of extracellular regions (ECRs) from ROR and RYK family members. Together with ligand-binding studies and other analyses, our structures suggest that WNT-attached fatty acids may play a different role in WNT binding to RTK co-receptors than in FZD binding – if they contribute at all. Our findings also suggest that WNT binding does not induce RTK homodimerization, and have implications for models of how WNTs might recruit RTK pseudokinases into FZD signaling complexes.

RESULTS AND DISCUSSION

In efforts to investigate how WNT-regulated RTKs are engaged by their ligands, we found that extracellular regions (ECRs) from *Drosophila melanogaster* ROR and RYK family members behaved best in biophysical and crystallization studies. The *Drosophila* ROR orthologs dRor and NrK (for neurospecific receptor tyrosine kinase; also called dRor2) are expressed specifically in the fly nervous system during embryogenesis (Oishi et al., 1997; Ripp et al., 2018). The three *Drosophila* RYK family members are Derailed (Drl), Drl-2 and Doughnut on 2 (Dnt). They play key roles in neuronal pathway selection (Callahan et al., 1995; Inaki et al., 2007) and muscle attachment site targeting (Callahan et al., 1996; Lahaye et al., 2012; Yoshikawa et al., 2001), as well as other aspects of fly nervous system function, including synaptic growth (Liebl et al., 2008), olfactory system patterning (Hing et al., 2020;

Sakurai et al., 2009; Wu et al., 2014), mushroom body development (Reynaud et al., 2015), and peripheral nervous system wiring (Yasunaga et al., 2015). Both ROR and RYK family receptors are thought to be regulated by the *Drosophila* WNT-5 ortholog, DWnt-5 (Lahaye et al., 2012; Ripp et al., 2018; Wouda et al., 2008; Yoshikawa et al., 2003).

Structure of the Nrk ECR

We first determined the crystal structure of the Nrk ECR (sNrk) to 1.75 Å resolution (Table 1). The dRor and Nrk ECRs both contain a FZD-like cysteine-rich domain (CRD) followed by a kringle (Kr) domain (Figure 1A), but lack the amino-terminal immunoglobulin (Ig)-like domain seen in human ROR1 and ROR2 (Roy et al., 2018). Our structure shows that the linker between the Nrk CRD and Kr domains is well ordered, with the two domains together forming a single unit (Figure 1B and C) – burying 1160 Å² of surface area between the two domains (580 Å² each). Parallel small angle X-ray scattering (SAXS) studies of the human ROR2 ECR (Figure S1A–D) indicate that the amino-terminal Ig-like domain in humans extends this globular structure into a longer rigid rod. As shown in Figure S1E, the Kr domain of sNrk overlays very well (RMSD < 2 Å, for all atoms) with those from human ROR1 (Qi et al., 2018) and ROR2 (Goydel et al., 2020), determined previously as fragments bound to potential therapeutic antibodies. The Nrk CRD closely resembles the CRD structures seen in FZDs (Dann et al., 2001; Nile and Hannoush, 2019), Smoothened (Nachtergaele et al., 2013), and MuSK (Stiegler et al., 2009). The domain is mostly α -helical, and is stabilized by 5 disulfide bonds that are very similar in location (and identical in connectivity) in all but the Smoothened CRD (Nachtergaele et al., 2013) – which lacks one disulfide bond. An amino-terminal hairpin-like structure precedes the first α -helix (α 1/2), and a β -hairpin (containing strands β 3 and β 4 in Nrk) connects α 3 and α 4 (using the secondary structure element numbering of Dann et al., 2001). In a Dali search (Holm, 2020) the Nrk CRD is most similar to that from rat MuSK (Figures 2A,B), with which it shares 30% sequence identity (Xu and Nusse, 1998). The Nrk and MuSK CRDs differ in significant ways from those in FZDs, among which the closest homolog of Nrk is FZD₄, with 17% sequence identity (Figure S2).

Key differences between the Nrk and FZD family CRDs

The first notable difference between ROR/MuSK and FZD CRDs is in the most N-terminal helical segment, which begins with a single helix (named α 1/2 here; Figure 2A,B) in Nrk and MuSK (Stiegler et al., 2009), but is split into two helices (α 1 and α 2) in FZD₈ (Figure 2C) and other FZD CRDs (Dann et al., 2001). The second difference involves a single-residue insertion before the eighth cysteine of ROR family and MuSK CRDs (Q157 in Nrk – see Figure S2A), which alters α 4 in a significant way. In FZD₈, the seventh and eighth cysteines are both in helix α 4, and form disulfide bonds with cysteines 9 and 3 respectively (Figure 2C), after which α 4 continues in the same direction. Inserting a residue before cysteine 8 causes a bulge and a bend in this helix for Nrk and MuSK (marked in Figures 2A,B) – effectively breaking the helix in two (helices α 4 and α 5), with important consequences for acyl chain binding as described below. Helix α 5 is also extended in Nrk, MuSK, and other RORs (Figure S2A), and the loop that connects α 5 to the C-terminal region of the domain is significantly longer in ROR and MuSK CRDs than the loop that connects α 4 to this region in FZD CRDs (Figure S2A).

The NrK CRD binds a fatty acid molecule

The NrK CRD has a bound fatty acid molecule (green in Figure 1B) that was not added during purification or crystallization. It is located within a large (~855 Å³) buried internal cavity between the CRD α -helices. The electron density for this feature is consistent with a 16-carbon fatty acid (Figure 2D), but we were not able to unambiguously determine the degree of unsaturation from our structure or by mass spectrometry. Considering palmitic (C16:0) and palmitoleic (C16:1) acids as the likely ligands, the carbon-carbon bond angles at the ⁹ position in our refined model were better fit with a freely rotating saturated palmitoyl chain, although a palmitoleoyl chain cannot be excluded. Interestingly, no similar internal cavity can be identified between the α -helices of other published CRD structures – including that from MuSK.

The NrK CRD fatty acid is deeply buried in the domain

Although fatty acids have been seen bound to several CRDs (Nile and Hannoush, 2019), the mode of fatty acid binding to the NrK CRD is quite different than seen for FZD and Smoothened CRDs (Byrne et al., 2016; Nile and Hannoush, 2019). The fatty acid molecule is completely buried in the middle of the NrK CRD – contacting side-chains from the middle of all four helices (α 1/2, α 3, α 4, and α 5; see Figure S2A), which together fully enshroud its ‘U’/‘C’-shaped aliphatic region. The carboxylate group of the fatty acid is also buried beneath the loop/insert that follows α 5 in NrK and connects it to the C-terminal part of the CRD (red in Figure 2E) – with the basic side-chains of K170, R179, and R183 ‘clamping’ the carboxylate in place (Figure 2D). As a result, the bound fatty acid appears completely inaccessible from the surface of the NrK CRD (Figures 2E and S2B) – and fully buried.

This complete burial of the bound fatty acid in the NrK CRD contrasts with the peripheral accommodation of fatty acids by FZD-family CRDs. Structures of *Xenopus* Wnt8 (Janda et al., 2012) or human WNT3 (Hirai et al., 2019) bound to the mFZD₈ CRD showed that the WNT-attached palmitoleic acid lies in a hydrophobic channel on the CRD surface (Figures 2F, S2C). Interestingly, the same surface-accessible channel was also occupied by a fatty acid molecule in structures of isolated CRDs from FZD₄ (Figure 2G), FZD₅ and FZD₇ (DeBruine et al., 2017; Nile et al., 2017) – even when no lipid was added during purification or crystallization. Moreover, the same surface-lying channel is utilized by human FZD₂ to bind a fatty acid (non-covalently) associated with the *Clostridium difficile* toxin B (TcdB) protein (Chen et al., 2018), and by the related Smoothened CRD in binding to cholesterol (Byrne et al., 2016). This channel is formed largely by helices α 2 and α 4 in mFZD₈ and mFZD₄ (Figures 2F,G), and the side-chains involved are well conserved across FZD family CRDs (Figure S2A). As shown in Figure 2H, the merging of helices α 1 and α 2 in NrK, without a bend between them, causes the end of helix α 1/2 to occlude the hydrophobic channel that is seen in FZD CRDs. In addition, the shortening of helix α 4 and its projection in a distinct direction (as helix α 5) removes the left-hand wall of the channel. Interestingly, the residues that contact the bound fatty acid largely appear similar in position in sequence alignments of ROR family and FZD CRDs (Figure S2A). However, whereas they lie in the channel between α 2 and α 4 in FZDs, they are instead in the C-terminal part of α 1/2 and in α 5 respectively in NrK – relocated in the structure because of the changes summarized above. The bend between α 4 and α 5, and the new direction of α 5 effectively create a

deeper fatty acid binding site in NrK than seen in other CRDs, which is also reached by side-chains from $\alpha 3$ (Figures 2D and S2B). In other words, the conserved fatty acid binding site is effectively relocated from the surface (where it lies in most CRDs) to the core of the NrK CRD domain (Figures S2B,C), and probably also in human RORs based on sequence similarity.

As shown in Figure S2, seven of the 19 side-chains that directly contact the bound fatty acid in NrK are identical in human ROR1 and/or ROR2 (L114, A122, L126, Y129, L146, L184, P185), and seven are similar (L/F, D/E, W/Y, I/A, and F/L substitutions). Only four are replaced with different residue types (L106, L110, M125, and T154 – replaced by threonine, serine and leucine respectively). These similarities argue that the CRDs of human ROR1 and ROR2 ECRs may bind fatty acids in a related way, although we were unable to identify lipids bound to human ROR ECRs secreted from Sf9 cells using mass spectrometry. The depth of the fatty acid bound in the CRD, and its inaccessibility from the domain's surface suggest that the lipid plays a co-factor role in this case, rather than playing a part in WNT protein binding.

Interestingly, the side-chains involved in fatty acid binding to NrK and FZD CRDs tend to be slightly less well conserved in MuSK. Moreover, the CASTp server (Tian et al., 2018) shows no significant cavities in the published MuSK CRD structure (Stiegler et al., 2009) that could accommodate an acyl chain of the type bound to sNrK or FZD CRDs.

The NrK CRD does not form dimers seen for FZD CRDs

One consequence of the fact that the bound fatty acid is fully buried in the NrK CRD (and likely in ROR1/2 CRDs) is that it cannot mediate CRD dimerization as reported for FZD CRDs (Nile and Hannoush, 2019). Indeed, both sNrK and the hROR2 ECR were monomeric by size exclusion chromatography and in sedimentation equilibrium analytical ultracentrifugation studies. Moreover, the only dimer interface that buries more than 400 Å² in the sNrK crystals is mediated primarily by the Kr domain (Figure S1F). By contrast, the isolated CRDs from FZDs 5, 7, and 8 all crystallized with a similar dimeric relationship that involves a characteristic α -helical dimer (Nile and Hannoush, 2019) and was also seen for the WNT3-bound mFZD₈ CRD (Hirai et al., 2019). These symmetric CRD dimers are mediated in part by $\alpha 1/\alpha 1$ and $\alpha 4/\alpha 4$ interactions (Figure S2D) – both helices that are altered structurally in ROR family CRDs. In addition, the hydrophobic channel formed between $\alpha 2$ and $\alpha 4$ in one FZD CRD molecule (Figure S2C) is apposed to the equivalent channel in its neighbor, so that a fatty acid bound in this channel can stabilize the dimer – spanning the interface as shown in Figure S2D (Hirai et al., 2019; Nile and Hannoush, 2019; Nile et al., 2017). Whereas fatty acid binding to peripheral locations on FZD family (and possibly Smoothened) CRDs appear to promote homo- or hetero-typic protein-protein interactions (DeBruine et al., 2017; Hirai et al., 2019; Nile and Hannoush, 2019), the structural features of ROR family CRDs do not appear to support this function.

A RYK/Drl WIF domain has no acyl chain binding site

We also determined the sDrl-2 structure to 2 Å resolution (Table 1). As illustrated in Figure 1A, RYK/Drl family proteins contain a WNT-Inhibitory Factor (WIF) domain in

their extracellular region (Callahan et al., 1995; Roy et al., 2018), which takes up almost the entire ECR (residues 26–161 of ~180 in Drl-2). As shown in Figure 3A, the Drl-2 WIF domain forms a 9-stranded β -sandwich with two short α -helices (α 1 and α 2) that are ‘presented’ at one of the splayed corners of the β -sandwich (Chothia, 1984). The Drl-2 WIF domain is very similar to the corresponding domain in WIF-1 (Liepinsh et al., 2006; Malinauskas et al., 2011) that is shown in Figure 3B.

An important key difference between the WIF domains from Drl-2 and WIF-1 is in their ability to accommodate a bound lipid in the middle of the β -sandwich. NMR studies of the WIF domain from WIF-1 (Liepinsh et al., 2006) suggested the existence of a significant internal cavity, suggested by docking studies to accommodate a fatty acid (Malinauskas, 2008). The subsequently determined WIF-1 crystal structure (Malinauskas et al., 2011) revealed that its WIF domain binds a dipalmitoylphosphatidylcholine (DPPC) molecule in the middle of the β -sandwich (Figure 3B). The aliphatic portion of the bound DPPC is buried within the hydrophobic core of the WIF domain, and the headgroup is accessible at the domain’s surface, in a manner reminiscent of ligand binding to lipocalins (Schiefner and Skerra, 2015). By contrast, the WIF domain of Drl-2 has a very well packed hydrophobic core (Figure 3C), in which no significant internal cavities could be found by the CASTp server (Tian et al., 2018). Indeed, the largest detectable cavity has a volume of just 77 \AA^3 , compared with 1,510 \AA^3 for the cavity in WIF-1 that accommodates DPPC.

This key distinction between the WIF domains from Drl-2 and WIF-1 can be explained based on sequence and structural differences. On one side of the WIF domain β -sandwich (Figure 3D, left), the secondary structure elements of Drl-2 and WIF-1 overlay very well – including α 1 plus strands β 1, β 2, β 4, and β 7, which are also among the most well conserved in sequence across WIF domains (Figure S3). The other half of the sandwich (Figure 3D, right) diverges much more. One key change is a 6-residue insertion between strand β 2 and helix α 2 in WIF-1 compared with Drl-2, colored magenta in Figures 3B, 3D, and S3. These additional residues form an extra 3_{10} helix in WIF-1, allowing this corner of the β -sandwich to be more splayed in WIF-1 than in Drl-2 (compare Figures 3A and B), and thus aiding accommodation of the DPPC molecule. Strand β 3 in Drl-2, which occludes the would-be DPPC binding site (Figure 3A), is not seen in the WIF-1 crystal structure because of this alteration. The second key change is in strand β 9, which is interrupted in WIF-1 by a loop and 4-residue insertion (including a proline), shown in magenta in Figures 3B, 3D, and S3. Whereas the contiguous strand β 9 of the Drl-2 WIF domain passes through the would-be DPPC binding site (Figures 3A,D) and occludes it, the insertion/bulge between β 9 and β 9’ in WIF-1 makes room for DPPC to bind to this WIF domain (Figures 3B,D). Thus, as a result of sequence differences between the class of WIF domains found in RYK/Drl family members and in WIF-1 orthologs respectively, the sDrl-2 structure described here shows that RYK/Drl WIF domains cannot accommodate a WNT-associated acyl chain when binding to their ligands, unlike the WIF domain from WIF-1 itself.

WNT binding by ROR and RYK/Drl family extracellular regions

The structures of both the Nrk CRD and the Drl-2 WIF domain argue that the ECRs of these WNT-binding RTKs could not engage an attached acyl chain when they bind to their

WNT ligands. The fatty acid molecule buried in the Nrk CRD core is unlikely to be capable of exchange with a WNT-attached fatty acid – contrasting with fatty acids bound in the readily accessible hydrophobic channels of FZD family CRDs (Figures S2B,C). Drl-2, as a representative of the RYK family, simply has no binding site to accommodate an acyl chain. Although these receptors have been shown to form complexes with WNTs (Reynaud et al., 2015; Ripp et al., 2018; Roy et al., 2018; Yoshikawa et al., 2003), it is important to ask whether the isolated ECRs are capable of interacting with the WNTs directly – for which we undertook ligand binding studies.

To investigate ligand binding by Nrk and Drl family proteins, we expressed and purified DWnt-5 (Eisenberg et al., 1992) in *Drosophila* Schneider-2 cells as described in Method Details. Note that DWnt-5 was also called DWnt-3 when it was first cloned (Fradkin et al., 1995; Russell et al., 1992). In our initial pull-down studies, DWnt-5 co-precipitated robustly with the histidine-tagged Drl ECR (sDrl₂₄₂) or Drl WIF domain (sDrl₁₈₃), as shown in Figure 4A. As a control, DWnt-5 did not co-precipitate significantly with the human PTK7 ECR. Pull-down experiments with the *Drosophila* ROR family ECRs gave substantially weaker signals than Drl, but significant (albeit low) levels of DWnt-5 could clearly be seen in pull-downs of histidine-tagged s-dRor (Figure 4A) – consistent with a previous report (Ripp et al., 2018) – but not of sNrK. In agreement with these findings, Drl family proteins showed robust DWnt-5 binding in surface plasmon resonance (SPR) experiments as described below (with submicromolar K_D values), but SPR studies of DWnt-5 binding to sNrK suggested K_D values in the range of 10 μ M or greater that we could not reliably measure. Turning to mammalian ROR family proteins for pull-down experiments, we produced murine WNT-5a in Expi293 cells as described previously (Speer et al., 2019), and found that the histidine-tagged ECR from human ROR2 could weakly co-precipitate mWNT-5a (Figure 4B), in agreement with previous reports (Billiard et al., 2005; Oishi et al., 2003) – although ROR1's ECR could not. Importantly, mutating the acylated serine in mWNT-5a to alanine (S244A) did not prevent ROR2 from binding WNT-5a in this assay. Together with the binding of DWnt-5 to s-dRor in Figure 4A, this result supports the argument that WNT acylation is not essential for WNT binding to ROR family CRDs – although these results certainly do not exclude a contributory role for WNT acyl chains in high-affinity ROR family binding.

Recombinant DWnt-5 is not acylated, but binds tightly to Drl family WIF domains

Having detected robust binding of recombinant DWnt-5 to sDrl as described above, we purified the ligand to investigate the interaction in more detail and to assess the importance of DWnt-5 acylation. As shown in Figure S4A, DWnt-5 contains a long (~550 aa) N-terminal 'prodomain' not seen in other WNT proteins, plus a ~150 amino acid insert within its WNT homologous domain (Eisenberg et al., 1992; Russell et al., 1992). Early studies showed that DWnt-5 is proteolytically processed when expressed in an imaginal disc cell line to yield a predominant ~80 kDa secreted species (Fradkin et al., 1995). DWnt-5 purified after expression in Schneider-2 (S2) cells was almost pure by Coomassie-stained SDS-PAGE (Figure 4C), running at just under 70 kDa (66 kDa by MALDI mass spectrometry). The protein was found by N-terminal sequencing to begin at residue 455 (sequence SQPSIS), which is ~100 residues before the WNT homologous

domain (Figure S4A). This protein, called DWnt-5(455-1004), is glycosylated at three sites that were identified by mass spectrometry as N484/485 (KVS MENNTSVTD), N724 (VDAKNDTSLV) and N952 (RVCHKNSSGLE). Deglycosylation with PNGase F reduces the apparent molecular weight of DWnt-5(455-1004) in SDS-PAGE to ~64 kDa (Figure S4B), compared with a predicted value of 62 kDa. Importantly, mass spectrometry of a tryptic digest of DWnt-5(455-1004) clearly identified a peptide fragment containing unmodified S868, the putative lipid modification site of DWnt-5. The tryptic peptide extending from C864-R884 (Figure 4D) had a mass corresponding to the unmodified peptide (other than addition of iodoacetamide at each cysteine). The facts that this peptide was detected with similar abundance to other DWnt-5 peptides, and that the acylated derivative could not be detected, argue that recombinant DWnt-5(455-1004) produced in S2 cells is not lipid modified at S868. This lack of lipid modification is also consistent with the solubility of DWnt-5 without detergent, and its migration as a monomeric protein in size exclusion chromatography (see Method Details).

We used SPR to assess binding of DWnt-5(455-1004) to Drl family ECRs. The ECRs of Drl, Drl-2 and Dnt all gave robust binding signals in SPR studies when DWnt-5 was immobilized on the Biacore CM5 sensor chip and purified ECR was flowed across this surface (Figure 4E). A representative sensorgram is shown in Figure S4C. The mean K_D for binding of the Drl ECR (sDrl₂₄₂) to immobilized DWnt-5 across multiple repeats was $0.72 \pm 0.16 \mu\text{M}$. The WIF domain alone (sDrl₁₈₃) bound with essentially the same affinity in parallel experiments (Figure S4D). The Drl-2 ECR bound DWnt-5 with similar affinity ($0.23 \pm 0.13 \mu\text{M}$), but the Dnt ECR bound ~10 fold more weakly. We further showed that this receptor binding was mediated by the Wnt homologous region of DWnt-5. As shown in Figure S4E, sDrl₁₋₂₄₂ binding was unaffected when the large insert in the WNT homologous region (residues 681-838) was replaced with the corresponding 13-aa insert (RERSFKRGSREQG) seen in Wnt-5 from the ant *Harpegnathos saltator* (Bonasio et al., 2010) to generate DWnt-5_{insert}. Note that DWnt-5 binding to immobilized Drl family ECRs gave higher apparent affinities (Figure 4F), consistent with aggregation on the sensorchip surface – as indicated by incomplete dissociation in Figure S2C (lower). Taken together, these data show that the *Drosophila* RYK/Drl family receptors bind DWnt-5 with affinities typical for RTK ligand binding, despite both the absence of a lipid modification on DWnt-5, and the absence of an acyl-chain docking site in the ECR of the receptor.

DWnt-5 binding does not promote sDrl dimerization

Since most RTKs undergo dimerization upon binding to their ligands (Lemmon and Schlessinger, 2010), we asked whether DWnt-5 might induce formation of sDrl dimers. Indeed, it has been reported that WNT-5a promotes hROR2 homodimerization (Liu et al., 2008) and that DWnt-5 drives Src64B recruitment to Drl by enhancing homodimerization of the receptor (Petrova et al., 2013). We used an in vitro pull-down assay to assess sDrl dimerization upon DWnt-5 binding (Figure 5A). Three different proteins were used: wild-type DWnt-5, FLAG-tagged sDrl₂₄₂, and V5-tagged sDrl₂₄₂. We incubated these proteins, either individually or in combination, with anti-FLAG conjugated to agarose beads and examined whether they could be pulled-down as a complex. DWnt-5 was efficiently pulled down by anti-FLAG when the FLAG-tagged sDrl₂₄₂ was present, consistent with the data

in Figure 4A, but the small amount of V5-tagged sDrl₂₄₂ seen in anti-FLAG pull-downs did not change with addition of FLAG-tagged sDrl₂₄₂ and/or DWnt-5 (compare lane 7 in lower blot of Figure 5A with lanes 3–5). Dimerization could also not be detected in solution biophysical studies. Thus, these experiments argue that DWnt-5 does not induce sDrl dimerization – consistent with an earlier suggestion that the transmembrane domain is likely to be the major driver of Drl dimerization (Petrova et al., 2013). We also note that the packing of sDrl-2 in crystals did not suggest any significant modes of ligand-independent ECR dimerization.

Possible location of the Drl/DWnt-5 binding interface

We next took two parallel approaches to identify which surface of the Drl family WIF domains is responsible for the strong DWnt-5 binding seen by SPR. In the first, we mutated conserved residues in the Drl WIF domain and directly assessed their effects on DWnt-5 binding. In the second, we used hydrogen-deuterium exchange mass spectrometry (HDX-MS) to locate regions in the Drl WIF domain that are protected upon binding to DWnt-5.

Aligning the sequences of WIF domains from Drl, Drl-2 and Dnt with those from RYK/Drl family members of humans and model organisms identified several highly conserved surface residues marked with asterisks in Figure S3. These include Y52 and F56 of Drl (equivalent to Y57 and F61 in $\alpha 2$ of Drl-2), which are conserved in all RYK/Drl WIF domains, and E40, V58, E126, and I154 of Drl (equivalent to D45, V58, Q132, and I159 in Drl-2), which are all conserved in type. We individually mutated these six residues in sDrl₂₄₂, and used SPR to assess the consequences for binding to immobilized DWnt-5. As shown in Figure 5B, glutamate substitutions at Y52, F56, or V58 (equivalent to Y57, F61, and V63 in Drl-2) essentially abolished DWnt-5 binding. Mutating E40 in sDrl to lysine (equivalent to D45 in Drl-2) had an intermediate effect, reducing affinity by ~10-fold, and E126K or I154E mutations in sDrl (equivalent to Q132K and I159E in Drl-2) had no effect. Mutating L41 or Y42 in sDrl (L46 or F47 in Drl-2) caused protein aggregation to be observed during purification by size exclusion chromatography, and so were not studied. These mutagenesis studies implicate the surface that includes the $\alpha 1/\beta 2$ loop, $\alpha 2$, and $\beta 3$ in DWnt-5 binding (Figure 5C). Consistent with these results, HDX-MS analysis of sDrl showed that DWnt-5 binding to sDrl led to the greatest protection from backbone amide proton exchange in regions encompassing $\beta 1-\alpha 1-\beta 2$, $\alpha 2$, and $\beta 3$ (Figure 5D; see also Figure S5A). Additional protection was also seen at the beginning of strand $\beta 8$ – an area that has several well-conserved surface side-chains. With the exception of strand $\beta 8$, these same parts of the Drl WIF domain showed the greatest backbone amine proton exchange in the absence of DWnt-5 (Figures S5B,C), suggesting that they are the most dynamic parts of the structure and are therefore likely alter conformation to accommodate DWnt-5 binding. The residues involved in DWnt-5 binding to Drl are in the same area of the WIF domain as those shown to be important for WNT3a binding to the WIF-1 WIF domain (Malinauskas et al., 2011) – in the region surrounding the splayed corner of the WIF domain β -sandwich that also allows accommodation of DPPC in WIF-1.

We also attempted to gain some insight into which surface of DWnt-5 is recognized by Drl in the same HDX-MS experiments. This was made very difficult, however, by poor MS

peptide coverage. Coverage was limited by the 11 disulfide bonds in DWnt-5 that must all be reduced for accurate assessment of mass changes in the individual constituent peptides. Full reduction of the disulfides is very difficult under the low temperature (and low pH) conditions required to minimize back exchange in HDX experiments, even with very high concentrations of reducing agent (Bobst and Kaltashov, 2014). As a result, we were not able to extend beyond ~50% sequence coverage in the WNT homologous domain even after optimization (Figure S6). Several key regions could nonetheless be tentatively excluded from the Drl-binding site based on an absence of alteration in HDX upon Drl binding (black in Figure 5E). These included the DWnt-5 peptide HGVSGSCS (865–872) that includes the potential palmitoleoylation site – suggesting that this ‘thumb’ region may not be involved in Drl binding. Only one region showed any degree of protection, with peptides (in a non-disulfide bonded region) spanning residues 920–927 (AHDLIYLD) and beyond (Figure 5E), which is in the ‘linker’ region that separates the large N-terminal domain (NTD) and smaller C-terminal domain (CTD) of DWnt-5 (Chu et al., 2013; Janda et al., 2012). These limited data are consistent with the possibility that Drl engages different WNT surfaces from those engaged by FZD CRDs. Studies of LRP6 binding to WNT3a (Chu et al., 2013) and of WNT7a binding to the Reck co-receptor (Eubelen et al., 2018) have similarly implicated the NTD/CTD linker region.

The Drl/DWnt-5 binding interface is required for Drl signaling in the *Drosophila* ventral nerve cord

Drl controls axon guidance in the developing central nervous system of *Drosophila* embryos (Callahan et al., 1995), specifically controlling which tracts axons use to cross the ventral midline. Drl is normally expressed in neurons that cross through the anterior commissure (AC), whereas those that cross through the posterior commissure (PC) normally do not express Drl, but do express DWnt-5. DWnt-5 in the PC functions as a repulsive signal, causing neurons that misexpress Drl to be redirected through the AC instead (Bonkowsky et al., 1999). This commissure switching by PC neurons that ectopically express Drl provides a useful quantitative *in vivo* assay for Drl function (Fradkin et al., 2004; Petrova et al., 2013; Yoshikawa et al., 2003), as summarized in Figure 6A.

We ectopically expressed wild-type Drl or an F56E-mutated variant (which has lost the ability to bind DWnt-5) in Eg^+ neurons that normally cross the ventral midline through the PC (left in Figure 6A), to assess whether they switch commissures. As shown in Figure 6B, expression of wild-type Drl resulted in robust commissure switching – quantitated in Figure 6C – whereas expression of the F56E variant did not (Figure 6B, right and Figure 6C). This finding indicates that mutating F56 impairs *in vivo* function of Drl as well as its *in vitro* binding to DWnt-5, and identifies F56E as a useful loss-of-function mutation for further *in vivo* dissection of RYK/Drl signaling.

CONCLUSIONS

Although it seems clear that ROR and RYK family members of the RTK superfamily play important roles in WNT signaling, their transmembrane signaling mechanisms are not yet understood (Green et al., 2014; Roy et al., 2018; Stricker et al., 2017). The CRD and WIF

domains in the ECRs of ROR and RYK family receptors clearly differ in detail from those seen in FZDs (Hirai et al., 2019; Janda et al., 2012) and WIF-1 (Kerekes et al., 2015; Malinauskas et al., 2011) – most notably in acyl chain docking sites. It is interesting that the NrK CRD resembles the WIF-1 WIF domain in having an apparently non-exchangeable bound acyl chain/lipid (Malinauskas et al., 2011), whereas this feature is absent from the Drl WIF domain. It is not clear how either NrK or Drl would accommodate the acyl chain bound to a WNT ligand, consistent with the possibility that other WNT epitopes dominate in binding to these RTKs.

Several studies indicate that ROR family members form WNT-dependent complexes with FZDs (Grumolato et al., 2010; Li et al., 2008; Nishita et al., 2010; Oishi et al., 2003). This would argue that the ROR and FZD CRDs recognize different regions of the WNT surface, possibly allowing the WNTs to crosslink FZDs and RORs – with the latter as co-receptors as suggested (Grumolato et al., 2010). RYK similarly appears to form WNT-dependent complexes with FZDs (Kim et al., 2008; Lu et al., 2004), consistent with a distinct epitope on the WNT for WIF domain binding.

Much remains to be learned about WNT biology. Recent advances in understanding WNT/FZD interactions have opened up key approaches for defining the roles of different FZD subtypes when brought together with LRP5/6 as a common co-receptor in this complex signaling axis (Miao et al., 2020; Tao et al., 2019; Tsutsumi et al., 2020). Our results reveal the distinct structural characteristics of known WNT-binding modules in RTK ECRs, which we expect will provide an initial basis for designing approaches to understand how recruiting different co-receptors to a given FZD defines signaling function. Thus, these data represent an important step in dissecting the roles of different co-receptor complexes in WNT biology.

STAR★METHODS

RESOURCE AVAILABILITY

Lead contact—Requests for further information or reagents may be directed to the lead contact, Mark A. Lemmon (mark.lemmon@yale.edu).

Materials availability—All unique and stable reagents generated in this study are available upon request from the lead contact.

Data and code availability

- Protein Data Bank (PDB) accession codes for the crystallographic coordinates and structure factors reported in this paper are:
PDB: 7ME4 (NrK/dRor2 ECR <http://www.rcsb.org/structure/7ME4>) and
PDB: 7ME5 (sDrl-2 ECR <http://www.rcsb.org/structure/7ME5>)
- All data reported in this paper will be shared by the lead contact upon request.
- This paper does not report original code.

- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

EXPERIMENTAL MODEL DETAILS

Cell lines and culture conditions

Insect cells: *Spodoptera frugiperda* Sf9 and *Trichoplusia ni* BTI-Tn-5B1-4 (High Five) cells were propagated at 27°C in serum-free ESF 921 Insect Cell Culture Medium (Expression Systems) containing 50 U/ml penicillin/streptomycin, and were used for production of secreted ECR proteins. Sf9 cells were originally established from immature ovaries of female *S. frugiperda* pupae, and BTI-Tn-5B1-4 cells from ovarian cells of the cabbage looper, *T. ni* and are also female. Schneider 2 (S2) cells were propagated at 24°C in Schneider's Insect Medium (Sigma) supplemented with 10% fetal calf serum or in EX-CELL 420 serum-free medium (SAFC Biosciences). S2 cells were originally established from a primary culture of late stage male *D. melanogaster* embryos.

Mammalian cells: Expi293 cells (female) were grown in suspension in Expi293 Expression medium supplemented with 100 U/ml penicillin/streptomycin at 37°C and 8% CO₂.

***Drosophila melanogaster* studies:** Standard *Drosophila* husbandry practices were followed. Fly strains were maintained on standard molasses-cornmeal-yeast food and were kept at 25°C with a 12 h dark cycle. Embryos were collected from 0–24 h at 20–25°C, starting late in the afternoon onto grapefruit agar plates smeared with yeast paste subsequent to a 3 h collection to purge females of retained older embryos. Crosses were established 24 h prior to the start of embryo collection.

METHOD DETAILS

Plasmid construction for recombinant protein expression—cDNA fragments encoding receptor ECRs were subcloned into pFastBac1 for expression in Sf9 or *T. ni* cells. The coding regions corresponded to:

s-dRor (UniProtKB – Q24488), aa 1–313 – with C-terminal hexahistidine tag;

sNrk/s-dRor2 (UniProtKB – Q9V6K3), aa 1–316 – with a C-terminal octahistidine tag;

s-hROR1 (UniProtKB – Q01973), aa 1–406 – with C-terminal hexahistidine tag;

s-hROR2 (UniProtKB – Q01973), aa 1–403 – with C-terminal hexahistidine tag;

sDrl₁₈₃ (UniProtKB – M9PDD9), aa 1–183 – with C-terminal hexahistidine tag;

sDrl₂₄₂ (UniProtKB – M9PDD9), aa 1–242 – with C-terminal hexahistidine tag;

sDrl-2 (UniProtKB – Q7JQT0), aa 1–183 – with a spacer peptide (RPLESRGPFEGKPIPNNLLGLDSTRTG) followed by a C-terminal hexahistidine tag;

sDrl-2/Xa (UniProtKB – Q7JQT0), aa 1–183 – followed by a C-terminal Factor Xa (FXa) cleavage site (IEGR), spacer peptide (ASGPFEGKPIPPLLGLDSTRTG) and a hexahistidine tag;

sDnt (UniProtKB – M9PG69), aa 1–208 – with a spacer peptide (RPLESRGPFEKGKPIPPLLGLDSTRTG) followed by a C-terminal hexahistidine tag.

For expression of wild-type DWnt-5 protein (UniProtKB – P28455), we used a pUAST plasmid containing the open reading frame of wild-type DWnt-5. To generate DWnt-5^{insert} protein, this plasmid was altered using site-directed mutagenesis to replace residues 681 to 838 of DWnt-5 was replaced with the short peptide sequence (RERSFKRGSREQG) found in the corresponding region of Wnt-5 from *Harpegnathos saltator* (Bonasio et al., 2010). Expression constructs for mWnt-5a expression were generated as described by Speer et al. (2019).

Protein production and purification

sNrk for crystallization: Recombinant baculovirus was generated using the Bac-to-Bac system (ThermoFisher Scientific), and sNrk was expressed in Sf9 cells grown in ESF921 medium (Expression Systems). Conditioned medium was collected 3 days after infection, diafiltered against 20 mM NaKPO₄, pH 8.0, containing 200 mM NaCl using a TFF2 10k-cutoff cartridge (Millipore), and loaded on to a Ni-NTA (Ni²⁺-nitrilotriacetate) column (Qiagen). The Ni-NTA resin was serially washed with the same buffer containing 10 mM, 20 mM and 30 mM imidazole (2 column volumes each), and then eluted in 20 mM NaKPO₄, pH 8.0, containing 200 mM NaCl and 200 mM imidazole. After dialysis in this buffer to remove imidazole, protein was then loaded on to Fractogel EMD SO₃⁻ cation exchange column (Millipore) in 20 mM MES, pH 6.0. After a step to 200 mM NaCl, protein was eluted with a gradient from 200 mM to 450 mM NaCl – eluting at 350–400 mM. Peak fractions were concentrated in an Amicon 10 concentrator, dialyzed into 20 mM HEPES, pH 8.0 containing 2.5 mM NaKPO₄ plus 125 mM NaCl, and passed through a Bio-Rad Bio-Scale CHT2-I ceramic hydroxyapatite column. The flow-through was then concentrated and subjected to size exclusion chromatography (SEC) on a Superose 6 column (GE Healthcare) in 20 mM HEPES, pH 7.5, containing 150 mM NaCl.

Other ROR family ECRs: s-dRor, s-hROR1 and s-hROR2 for pull-down experiments and SAXS experiments (s-hROR2 in Figure S1) were produced using essentially the same approach as described for sNrk, but omitting the hydroxyapatite chromatography step.

sDrl, sDrl-2, and sDnt proteins: Recombinant baculoviruses encoding Drl family ECRs were used to infect Sf9 cells (*T. ni* cells for sDrl-2 for crystallization) grown in ESF921 medium (Expression Systems). Conditioned medium was harvested three days after infection and subjected to extensive dialysis at 4°C against 20 mM HEPES pH 7.5, 150 mM NaCl. Proteins were then loaded onto Ni-NTA beads, which were washed twice with low imidazole buffer (20 mM HEPES pH 7.5, 150 mM NaCl and 15 mM imidazole) prior to elution of protein with buffer containing 20 mM HEPES pH 7.5, 150 mM NaCl and 100 mM imidazole. Drl family ECRs were further purified using an UnoQ anion exchange column (Bio-Rad), loading in 20 mM HEPES pH 7.5 containing 70 mM NaCl and using

an elution gradient of 70 mM-1 M NaCl. Peak fractions were then subjected to SEC using a Superose 12 column (GE Healthcare) in 10 mM HEPES pH 7.5, containing 150mM NaCl. All mutated sDrl variants purified similarly, with all but the L41E and Y42E variants (which were excluded from study) eluting in SEC as well behaved monomers. sDrl-2 for crystallization was further subjected to Factor Xa protease (10 µg protease per mg of sDrl-2 in 1 ml for 1 h at room temperature) to remove the hexahistidine tag, and was then subjected to anion exchange and SEC. sDrl-2 for crystallization was also partially deglycosylated with PNGase F (New England BioLabs: 2,000 unit/mg sDrl-2) for 3 h at room temperature before SEC.

DWnt-5 purification: S2 cells were transfected with a mixture of three plasmids (*i*) pUAST-DWnt-5, (*ii*) pAc-Gal4 and (*iii*) pCoHygro (10µg:10µg:1µg) using the calcium phosphate method, and were selected in Schneider's Insect Medium (Sigma) supplemented with 10% fetal calf serum (Sigma, Cat# F0643) and 300 µg/ml hygromycin (Cellgro) for 3 weeks. The Schneider's Insect Medium was then replaced with EX-CELL 420 serum-free medium (SAFC Biosciences) for subsequent cell culture, and constitutive secretion of DWnt-5 into the medium was verified using DWnt-5 specific antibodies. For DWnt-5 expression, cells were seeded at 4×10^6 cells/ml in spinner flasks. After 5 days of growth, medium (~3 l) was harvested and flowed through a 4 ml Fractogel SO₃⁻ (EMD Millipore) cation exchange column at 4°C. The column was then washed twice with 10 ml of wash buffer (20 mM HEPES, pH 7.5 containing 250 mM NaCl), and DWnt-5 was eluted in 20 mM HEPES, pH 7.5 containing 900 mM NaCl in three washes of 4 ml each. The eluted protein was then diluted with 3 volumes of 20 mM HEPES, pH 7.5 to lower [NaCl] to <250 mM, and was loaded onto a second 2 ml Fractogel SO₃⁻ AKTA column at room temperature, pre-equilibrated in 20 mM HEPES, pH 7.5 and 150 mM NaCl. DWnt-5 was eluted with a gradient from 150 mM to 1 M NaCl in this buffer, eluting at around 650 mM NaCl. The eluted fractions were then diluted again with 3 volumes of 20 mM HEPES, pH 7.5 and loaded onto a 2 ml CHT2-I hydroxyapatite column (Bio-Rad) equilibrated in 20 mM HEPES, pH 7.5 containing 150 mM NaCl, 2.5 mM NaH₂PO₄, and 2.5 mM K₂HPO₄. A gradient from 0–100% of Buffer B (20 mM HEPES, pH 7.5 containing 150 mM NaCl, 250 mM NaH₂PO₄, and 250 mM K₂HPO₄) was then applied. Eluted fractions were pooled, concentrated in a centrifugal concentrator, and subjected to SEC on a Superose 6 column (GE Healthcare) in 10 mM HEPES, pH 7.5 containing 150 mM NaCl. Then purified DWnt-5 protein could be flash frozen following addition of 10% glycerol with no significant aggregation or loss of sDrl-binding activity upon thawing.

mWnt-5a production: mWnt-5a-containing conditioned medium was prepared as described (Speer et al., 2019) by expressing wild-type or acylation-site-mutated mWnt-5a using the Expi293™ Expression System (ThermoFisher Scientific) according to the manufacturers' instructions. Expi293 cells were transfected with plasmids encoding wild-type or mutated mWnt-5a under control of a CMV promoter. The culture medium was harvested 96 h post-transfection and cleared by centrifugation for use in co-precipitation assays.

Crystallization and structure determination

sNrk: For sNrk, the protein was concentrated to ~3 mg/ml. Crystals were grown at 21°C using the hanging drop vapor diffusion method, mixing equal volumes of protein solution and well solution containing 50 mM Bis-Tris propane (pH 5.0), 20% PEG 3350. Crystals grew in a few days, and were cryoprotected by weaning into the same solution containing 18% sucrose. Frozen crystals diffracted to 1.75 Å at APS beamline 24-ID-E. Initial phasing was obtained using mr_rosetta (Terwilliger et al., 2012), which identified a starting model based on the MuSK CRD (Stiegler et al., 2009) and the 7th Kr domain in apolipoprotein-a (Ye et al., 2001), with PDBIDs 3HKL and 1I71 respectively. Structural refinement and model building were then carried out iteratively using Refmac (CCP4, 1994), Phenix (Adams et al., 2010), and Coot (Emsley and Cowtan, 2004).

sDrl-2: Purified sDrl-2 protein was concentrated to >12 mg/ml for crystallization. Crystals were grown at 21°C using the hanging drop vapor diffusion method by mixing 1 µl protein solution with 1 µl well solution containing 100 mM Tris pH 8.5, 25% PEG 6000, 100 mM sodium acetate, and 15% glycerol. Crystals formed within 2 days and were frozen directly in liquid nitrogen. Data were collected to 1.95 Å resolution on a HighFlux HomeLab X-ray diffraction unit (Rigaku) with a Saturn 944 CCD detector, and were processed using HKL2000 software. Initial phasing was obtained by molecular replacement using a truncated poly-alanine model of the NMR structure (Liepinsh et al., 2006) of the WIF domain from hWIF-1 (PDB: 2D3J) as the search model in Phaser (CCP4, 1994). Structural refinement and model building were carried out using Refmac (CCP4, 1994), Phenix (Adams et al., 2010), and Coot (Emsley and Cowtan, 2004).

in vitro pull-down assays for binding assessment

DWnt-5 interactions: Purified histidine-tagged sDrl, sNrk, or s-dRor at ~0.5 µM (or the human PTK7 ECR as control) were mixed with a similar concentration of DWnt-5 and incubated with nutation for 30 min at 4°C in 20 mM HEPES pH 7.5, 150 mM NaCl. Ni-NTA beads were then added, pelleted, and washed extensively in buffer prior to immunoblotting with anti-DWnt-5 (upper panel of Figure 4A) or anti 6xHis (lower panel of Figure 4A).

hROR-mWnt-5a binding: Conditioned medium from Expi293 cells expressing wild-type or S244A-mutated mWnt-5a was added to ~0.5 µM histidine-tagged s-hROR1 or s-hROR2 (or s-hEGFR₅₀₁ as a control) in 20 mM HEPES pH 7.5, 100 mM NaCl for 30 min at 4°C. Ni-NTA beads were then added, pelleted, and washed extensively in buffer prior to immunoblotting with anti-Wnt-5a (upper panel of Figure 4B) or anti 6xHis (lower panel of Figure 4B). Note that pixel binning was used to increase sensitivity for detecting the weak anti-Wnt-5a signal in the upper panel of Figure 4B, reducing spatial resolution of this blot image.

Assessment of DWnt-5-induced sDrl dimerization: Two variants of sDrl₂₄₂ were generated, with a V5-tag (GKPIPPLLGLDSTGHHHHHH) and FLAG-tag (DYKDDDDKGGHHHHHH) respectively after residue 242, and were produced in Sf9 cells using the approaches outlined above. In a total volume of 400 µl, 200 nM of sDrl-V5 and

100 nM sDrl-FLAG were mixed with 300 nM DWnt-5 and 15 μ g anti-FLAG M2 in 20 mM HEPES pH 7.5, 150 mM NaCl and 0.2% (w/v) BSA. After 30 min at 4°C, 150 μ l of Protein G Dynabeads (Invitrogen) were washed and added to the mixture, which was incubated for an additional hour. Supernatant and Dynabeads were then separated using a magnet, and Dynabeads were resuspended in equal volumes of buffer for immunoblotting anti-DWnt-5 (upper panel in Figure 5A), anti-FLAG (middle panel in Figure 5A) and mouse anti-V5 (lower panel in Figure 5A).

Surface Plasmon Resonance (SPR)—SPR experiments were performed using a Biacore3000 instrument (GE Healthcare). DWnt-5 protein was immobilized on CM5 sensorchips using the amine coupling method recommended by the manufacturers, typically immobilizing ~10,000 resonance units (RUs) onto the surface. Purified sDrl at a series of concentrations (4 nM – 20 μ M; starting at the lowest concentration) in 10 mM HEPES (pH 8.0), 150 mM NaCl, 3 mM EDTA and 0.005% Surfactant P-20 was then injected at 10 μ l/min at room temperature until steady state was reached. Following each injection, bound sDrl was allowed to spontaneously dissociate from the sensorchip surface in the same buffer. Steady-state signals were background-corrected by subtracting the signal obtained with a control surface. For estimation of binding affinities, SPR signal values were plotted against [sDrl] and fit to a simple single-site saturation-binding model in Prism 9.

For the reverse experiment (immobilizing sDrl homologues and flowing DWnt-5 protein across the resulting surfaces), purified ECRs at 25 μ M (in 8 mM HEPES pH 7.5, 120 mM NaCl, 10% glycerol) were diluted 1:4 in 10 mM sodium acetate, pH 4.5, and flowed across an activated CM5 sensorchip surface for 9 min at 10 μ l/min prior to quenching with 1 M ethanolamine. Approximately 10,000–14,000 RUs of each sDrl protein were thus immobilized. Purified DWnt-5 was then injected at a range of concentrations (10 nM – 5 μ M) until steady state was reached (typically ~7 min at 10 μ l/min). In this case, regeneration with a 25 μ l injection of 10 mM sodium acetate, pH 4.5 containing 500 mM NaCl was required between injections to remove residual DWnt-5 from the sensorchip surface.

Small angle X-ray scattering (SAXS)—The SAXS data used for Figures S1A–D were recorded using beam line G1 at CHESS, for s-hROR2 at 11.3 mg/ml (270 μ M) in 25 mM MES, 150 mM NaCl, pH 6.0. Data were collected in 2010 on a custom 1024 \times 1024 (69.78 μ m) pixel CCD detector constructed by the Grüner group (Cornell University, Ithaca, NY, USA). Two-dimensional images were integrated using Data Squeeze 2.07 (Datasqueeze Software, Wayne, PA, USA) to give one-dimensional intensity profiles as a function of q ($q = 4\pi\sin\theta/\lambda$, where 2θ is the scattering angle). Measurements were taken at room temperature with a sample-to-detector distance of 1,175 mm. With a calibrated wavelength of 1.256 Å, scattering profiles covered a q range from 0.008 to 0.294 Å⁻¹. The incident X-ray beam was collimated to a spot size measuring 0.5 \times 0.5 mm², which was significantly smaller than the opening of the sample cells. Exposure times ranged from 4 s with no attenuation, and measurements were made in triplicate unless otherwise noted. Capillary quartz sample cells holding approximately 35 μ l were used, with volume oscillation during data collection to help protect from radiation damage.

Data were corrected for incident radiation and scattering from a buffer match (against which the sample had been dialyzed) to yield the scattering profile (Figure S1C) in which intensity (I) is plotted as a function of q . Guinier analysis (Figure S1D) was performed using PRIMUS (Konarev et al., 2003). Pair-distance distribution functions (Figure S1B) were generated from the scattering profiles using the program GNOM (Semenyuk and Svergun, 1991), and results corroborated using an automated implementation of the program called AUTOGNOM (Petoukhov et al., 2007). The maximum diameter of the protein (d_{\max}) was adjusted in 10 Å increments in GNOM to maximize the goodness-of-fit parameter. This analysis also yielded an R_g determination. Low resolution shapes/most probable envelopes were determined from SAXS data using the program DAMMIF (Franke and Svergun, 2009). Ten independent calculations were performed for each data set, using default parameters with no symmetry assumptions. The models resulting from these independent runs were superimposed using the program SUPCOMB based on the normalized spatial discrepancy (NSD) criterion – with NSD values of 0.6–0.7 (Kozin and Svergun, 2001). The ten independent reconstructions were then averaged and filtered to a final consensus model using the DAMAVER suite of programs (Volkov and Svergun, 2003).

Mass spectrometry analysis for identification and post-translational modification—Mass spectrometry analysis of trypsinized DWnt-5 and other proteins – as well as small molecule analysis – was provided by the Proteomics Core Facility at the Children’s Hospital of Philadelphia, using standard protocols for gel purified protein identification. Protein was treated with 10 mM iodoacetamide to reduced disulfide bonds and alkylate free cysteines. For identification of glycosylation sites, PNGase F treatment in ^{18}O water was performed as described (Cao et al., 2018) prior to LC MS/MS analysis.

Hydrogen-Deuterium exchange-mass spectrometry (HDX-MS)—For HDX-MS analysis of sDrl, the exchange reaction was initiated by mixing the sDrl N63Q/N143Q double mutant protein stock (28.5 μM , in 20 mM HEPES pH 7.4, 200 mM NaCl) into a 96% D_2O solution containing 150 mM NaCl at a ratio of 1:4 (v:v). For the sDrl/DWnt-5 complex, a protein mixture containing 28.5 μM sDrl and 29.5 μM DWnt-5 was similarly diluted into 96% D_2O (150 mM NaCl). Final concentrations of sDrl and DWnt-5 in the exchange reactions were thus 5.7 μM and 5.9 μM , respectively. The pD of each HDX reaction solution was estimated to be 7.2 ($\text{pH}_{\text{read}} + 0.4$). HDX reactions were carried out at 0°C. At each time point (10 s, 10^2 s, 10^3 s, 10^4 s and 10^5 s), a 15 μl aliquot of the reaction mixture was quenched by adding 45 μl of quench buffer (1.5 M guanidine hydrochloride, 50 mM tris-(2-carboxyethyl)phosphine (TCEP), 0.8% formic acid and 10% glycerol). As controls, non-deuterated (‘all-H’) and fully deuterated (‘all-D’) samples were prepared in the same way. All samples were frozen in liquid nitrogen immediately after adding quench buffer. For experiments seeking DWnt-5 peptides, the quench buffer was switched to 500 mM TCEP, pH 2.8 with 500 mM glycine/HCl as buffer agent - to maximize the number of reduced peptides while not having significant back exchange effects.

Prior to data collection, frozen samples were quickly thawed on ice and injected at a flow rate of 100 $\mu\text{l}/\text{min}$ into a thermoelectrically cooled chamber (Mayne et al., 2011). The sample was digested on an immobilized pepsin column within the cooled chamber. Digested

peptides were flowed through a Piccolo C18 trap column (Higgins Analytical) to desalt the peptide fragments. An acetonitrile gradient (10–55% acetonitrile, 0.1% TFA) was then used to elute peptides from the trap column and into an analytical C18 column (5 cm × 0.3 mm, Targa 3 μm C18 resin, Higgins Analytical). The effluent was flowed directly to Thermo LTQ Orbitrap XL mass spectrometer for electrospray ionization. A tandem MS (CID mode) run was carried out for the ‘all-H’ sample in order to identify the sequences of digested peptides. SEQUEST (Bioworks, version 3.3.1) was used to identify peptides from the tandem MS data. The MATLAB-based data analysis tool ExMS (Kan et al., 2011) was used to validate peptide assignments and subsequently to compute the centroid of isotopic distribution of each deuterated peptide. The ‘All-D’ sample was included to calibrate back-exchange of the deuterated samples. Details of ExMS-based data collection and the data processing workflow are described by Kan et al. (2011). NumPy and Matplotlib (Hunter, 2007) were used to export the ExMS results to the Python environment for further analysis and plotting. To assess the differences in HDX rates within sDrl with- and without bound DWnt-5, the difference in number of exchanged deuterons was calculated for each peptide at each time point. The maximum difference among all of the time points was further divided by the number of amide hydrogen atoms in the peptide to give a weighted relative HDX difference for each peptide, which was visualized in Figures 5D,E and S5 by color coding the sDrl homology model according to this ‘weighted relative difference’.

***Drosophila* commissure switching assays**—The F56E mutation was introduced into the Drl coding region in the pENTR vector using oligonucleotide-mediated mutagenesis, and the open reading frame was subsequently transferred into pTWM-attB (L.G.F., unpublished) using LR Clonase (ThermoFisher Scientific) to generate Drl-F56E-(6x)-Myc. Transgenic lines of both wild-type Drl and Drl-F56E were then generated by pH31-mediated transgenesis using the pBac{yellow[+] attP-9A}VK00027 stock (attP inserted at cytogenetic location 89E11) at Bestgene, Inc. to ensure equivalent expression of both species. A representative line of each was then crossed with the eg-GAL4 driver line with an insert of wild-type pTWM-Drl that shows minimal posterior to anterior commissure switching of the Eg+ neurons on its own (“sensitized background”). Embryos were collected from 0–24 hours at 20–25°C, starting late in the afternoon onto grapefruit agar plates smeared with yeast paste subsequent to a 3 h collection to purge females of retained older embryos. Crosses were established 24 hours prior to the start of embryo collection. 0–24 h embryos were collected, devitelinized and stained with rabbit anti-Myc (ThermoFisher Scientific) followed by HRP-conjugated goat anti-rabbit (ThermoFisher Scientific) and were visualization by incubation with a 3,3'-diaminobenzidine (DAB)/hydrogen peroxidase solution. Embryos were cleared by stepwise incubation with increasing concentrations of glycerol in phosphate-buffered saline, ventral nerve cords were dissected and mounted on slides and were then scored blinded to genotype. Controls included the sensitized background stock and pTWM-GFP (inserted at the same attP site) in the sensitized background. At least 400 hemisegments were scored for each genotype.

QUANTIFICATION AND STATISTICAL ANALYSIS

Structure determination and analysis—Statistics for the structural models are provided in Table 1. Analysis of molecular contacts and RMSD values were calculated using the CCP4 software package (CCP4, 1994).

SPR data analysis—Where K_D values are quoted, experiments were performed at least three times with different protein preparations – to achieve at least 3 biological replicates. K_D values are quoted \pm SD.

Analysis of HDX dynamics—Raw mass spectra of undeuterated controls were used for peptide identification using SEQUEST (Bioworks, Version 3.3.1). All raw spectra for each peptide, labeling condition, drug condition, and charge state were then manually assessed for quality and for accurate peak assignment, at which point poor quality or incorrectly assigned peaks were unassigned. The MATLAB-based software ExMS (Kan et al., 2011) was used to validate peptide assignment and to determine average mass shifts of centroids and their standard deviations to calculate percent uptake for each time point relative to a fully deuterated standard as described in Method Details.

Western blot image processing—Raw images from a Kodak Image Station (Figures 4B,C, 5A, and S4B) or LI-COR Odyssey Fc imager (Figure 4A) were imported in Adobe Photoshop, and the ‘Levels’ function used to apply a linear correction (bring up background, bring down upper limit) so that the darkest points of all images are black, and the background is brought into the visible grey scale in order to register all features in the image. Note that X and Y pixel binning was used to increase sensitivity for the upper panel in Figure 4B because weak ROR2/WNT-5a interactions give only weak, but highly reproducible ($n>4$), signals. This X/Y binning compromises the spatial resolution of the blot image.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGEMENTS

We thank members of the Lemmon and Ferguson labs for comments on the manuscript, and Richard Gillilan (CHESS) and Kushol Gupta (U. Penn) for help with SAXS data collection and analysis. This work was supported by NIGMS grants R35-GM122485 (to M.A.L.) and R01-GM031847 (to S.W.E), T32-GM007229 (to K.F.S.), an NSF Graduate Research Fellowship (DGE1122492 to J.B.S.) NSF grant MCB1020649 (to S.W.E.), and by the Deutsche Forschungsgemeinschaft (SO 1729/1-1 to A.S.). Synchrotron SAXS data were collected at MacCHESS beamline G1. CHESS was supported by NSF award DMR-0936384, and the MacCHESS resource by NIH/NIGMS award GM-103485. NE-CAT at the Advanced Photon Source (APS) is supported by a grant from NIGMS (P30 GM124165). APS is a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract No. DE-AC02-06CH11357.

REFERENCES

Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, et al. (2010). PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr. D Biol. Crystallogr* 66, 213–221. [PubMed: 20124702]

- Billiard J, Way DS, Seestaller-Wehr LM, Moran RA, Mangine A, and Bodine PV (2005). The orphan receptor tyrosine kinase Ror2 modulates canonical Wnt signaling in osteoblastic cells. *Mol. Endocrinol* 19, 90–101. [PubMed: 15388793]
- Bobst CE, and Kaltashov IA (2014). Enhancing the quality of H/D exchange measurements with mass spectrometry detection in disulfide-rich proteins using electron capture dissociation. *Anal. Chem* 86, 5225–5231. [PubMed: 24820935]
- Bonasio R, Zhang G, Ye C, Mutti NS, Fang X, Qin N, Donahue G, Yang P, Li Q, Li C, et al. (2010). Genomic comparison of the ants *Camponotus floridanus* and *Harpegnathos saltator*. *Science* 329, 1068–1071. [PubMed: 20798317]
- Bonkowski JL, Yoshikawa S, O'Keefe DD, Scully AL, and Thomas JB (1999). Axon routing across the midline controlled by the *Drosophila* Derailed receptor. *Nature* 402, 540–544. [PubMed: 10591215]
- Bourhis E, Tam C, Franke Y, Bazan JF, Ernst J, Hwang J, Costa M, Cochran AG, and Hannoush RN (2010). Reconstitution of a frizzled8.Wnt3a.LRP6 signaling complex reveals multiple Wnt and Dkk1 binding sites on LRP6. *J. Biol. Chem* 285, 9172–9179. [PubMed: 20093360]
- Byrne EFX, Sircar R, Miller PS, Hedger G, Luchetti G, Nachtergaele S, Tully MD, Mydock-McGrane L, Covey DF, Rambo RP, et al. (2016). Structural basis of Smoothed regulation by its extracellular domains. *Nature* 535, 517–522. [PubMed: 27437577]
- Callahan CA, Bonkovsky JL, Scully AL, and Thomas JB (1996). Derailed is required for muscle attachment site selection in *Drosophila*. *Development* 122, 2761–2767. [PubMed: 8787750]
- Callahan CA, Muralidhar MG, Lundgren SE, Scully AL, and Thomas JB (1995). Control of neuronal pathway selection by a *Drosophila* receptor protein-tyrosine kinase family member. *Nature* 376, 171–174. [PubMed: 7603568]
- Cao L, Diedrich JK, Ma Y, Wang N, Pauthner M, Park SR, Delahunty CM, McLellan JS, Burton DR, Yates JR, et al. (2018). Global site-specific analysis of glycoprotein N-glycan processing. *Nat. Protoc* 13, 1196–1212. [PubMed: 29725121]
- CCP4 (1994). The CCP4 suite: Programs for protein crystallography. *Acta Crystallogr. D Biol. Crystallogr* 50, 760–763. [PubMed: 15299374]
- Chen P, Tao L, Wang T, Zhang J, He A, Lam KH, Liu Z, He X, Perry K, Dong M, et al. (2018). Structural basis for recognition of frizzled proteins by Clostridium difficile toxin B. *Science* 360, 664–669. [PubMed: 29748286]
- Chothia C (1984). Principles that determine the structure of proteins. *Annu. Rev. Biochem* 53, 537–572. [PubMed: 6383199]
- Chu ML, Ahn VE, Choi HJ, Daniels DL, Nusse R, and Weis WI (2013). Structural studies of Wnts and identification of an LRP6 binding site. *Structure* 21, 1235–1242. [PubMed: 23791946]
- Dann CE, Hsieh JC, Rattner A, Sharma D, Nathans J, and Leahy DJ (2001). Insights into Wnt binding and signalling from the structures of two Frizzled cysteine-rich domains. *Nature* 412, 86–90. [PubMed: 11452312]
- DeBruine ZJ, Ke J, Harikumar KG, Gu X, Borowsky P, Williams BO, Xu W, Miller LJ, Xu HE, and Melcher K (2017). Wnt5a promotes Frizzled-4 signalosome assembly by stabilizing cysteine-rich domain dimerization. *Genes Dev.* 31, 916–926. [PubMed: 28546512]
- Eisenberg LM, Ingham PW, and Brown AM (1992). Cloning and characterization of a novel *Drosophila* Wnt gene, Dwnt-5, a putative downstream target of the homeobox gene distal-less. *Dev. Biol* 154, 73–83. [PubMed: 1358729]
- Emsley P, and Cowtan K (2004). Coot: model-building tools for molecular graphics. *Acta Crystallogr. D Biol. Crystallogr* 60, 2126–2132. [PubMed: 15572765]
- Eubelen M, Bostaille N, Cabochette P, Gauquier A, Tebabi P, Dumitru AC, Koehler M, Gut P, Alsteens D, Stainier DYR, et al. (2018). A molecular mechanism for Wnt ligand-specific signaling. *Science* 361, eaat1178. [PubMed: 30026314]
- Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ, and Lemmon MA (2003). EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. *Mol. Cell* 11, 507–517. [PubMed: 12620237]
- Fradkin LG, Dura JM, and Noordermeer JN (2010). Ryks: New partners for Wnts in the developing and regenerating nervous system. *Trends Neurosci.* 33, 84–92. [PubMed: 20004982]

- Fradkin LG, Noordermeer JN, and Nusse R (1995). The *Drosophila* Wnt protein DWnt-3 is a secreted glycoprotein localized on the axon tracts of the embryonic CNS. *Dev. Biol* 168, 202–213. [PubMed: 7883074]
- Fradkin LG, van Schie M, Wouda RR, de Jong A, Kamphorst JT, Radjkoemar-Bansraj M, and Noordermeer JN (2004). The *Drosophila* Wnt5 protein mediates selective axon fasciculation in the embryonic central nervous system. *Dev. Biol* 272, 362–375. [PubMed: 15282154]
- Franke D, and Svergun DI (2009). DAMMIF, a program for rapid ab-initio shape determination in small-angle scattering. *J. Appl. Cryst* 42, 342–346. [PubMed: 27630371]
- Goydel RS, Weber J, Peng H, Qi J, Soden J, Freeth J, Park H, and Rader C (2020). Affinity maturation, humanization, and co-crystallization of a rabbit anti-human ROR2 monoclonal antibody for therapeutic applications. *J. Biol. Chem* 295, 5995–6006. [PubMed: 32193207]
- Green J, Nusse R, and van Amerongen R (2014). The role of Ryk and Ror receptor tyrosine kinases in Wnt signal transduction. *Cold Spring Harb. Perspect. Biol* 6, a009175. [PubMed: 24370848]
- Green JL, Kuntz SG, and Sternberg PW (2008). Ror receptor tyrosine kinases: orphans no more. *Trends Cell Biol.* 18, 536–544. [PubMed: 18848778]
- Grumolato L, Liu G, Mong P, Mudbhary R, Biswas R, Arroyave R, Vijayakumar S, Economides AN, and Aaronson SA (2010). Canonical and noncanonical Wnts use a common mechanism to activate completely unrelated coreceptors. *Genes Dev.* 24, 2517–2530. [PubMed: 21078818]
- Hing H, Reger N, Snyder J, and Fradkin LG (2020). Interplay between axonal Wnt5-Vang and dendritic Wnt5-Drl/Ryk signaling controls glomerular patterning in the *Drosophila* antennal lobe. *PLoS Genet.* 16, e1008767. [PubMed: 32357156]
- Hirai H, Matoba K, Mihara E, Arimori T, and Takagi J (2019). Crystal structure of a mammalian Wnt-frizzled complex. *Nat. Struct. Mol. Biol* 26, 372–379. [PubMed: 31036956]
- Holm L (2020). DALI and the persistence of protein shape. *Protein Sci.* 29, 128–140. [PubMed: 31606894]
- Hsieh JC, Kodjabachian L, Rebbert ML, Rattner A, Smallwood PM, Samos CH, Nusse R, Dawid IB, and Nathans J (1999). A new secreted protein that binds to Wnt proteins and inhibits their activities. *Nature* 398, 431–436. [PubMed: 10201374]
- Hunter JD (2007). Matplotlib: A 2D graphics environment. *Comput. Sci. Eng* 9, 90–95.
- Inaki M, Yoshikawa S, Thomas JB, Aburatani H, and Nose A (2007). Wnt4 is a local repulsive cue that determines synaptic target specificity. *Curr. Biol* 17, 1574–1579. [PubMed: 17764943]
- Janda CY, Dang LT, You C, Chang J, de Lau W, Zhong ZA, Yan KS, Marecic O, Siepe D, Li X, et al. (2017). Surrogate Wnt agonists that phenocopy canonical Wnt and beta-catenin signalling. *Nature* 545, 234–237. [PubMed: 28467818]
- Janda CY, and Garcia KC (2015). Wnt acylation and its functional implication in Wnt signalling regulation. *Biochem. Soc. Trans* 43, 211–216. [PubMed: 25849919]
- Janda CY, Waghray D, Levin AM, Thomas C, and Garcia KC (2012). Structural basis of Wnt recognition by Frizzled. *Science* 337, 59–64. [PubMed: 22653731]
- Jing L, Lefebvre JL, Gordon LR, and Granato M (2009). Wnt signals organize synaptic prepattern and axon guidance through the zebrafish unplugged/MuSK receptor. *Neuron* 61, 721–733. [PubMed: 19285469]
- Kan ZY, Mayne L, Chetty PS, and Englander SW (2011). ExMS: data analysis for HX-MS experiments. *J. Am. Soc. Mass Spectrom* 22, 1906–1915. [PubMed: 21952778]
- Kelley LA, Mezulis S, Yates CM, Wass MN, and Sternberg MJ (2015). The Phyre2 web portal for protein modeling, prediction and analysis. *Nat. Protoc* 10, 845–858. [PubMed: 25950237]
- Kerekes K, Bányai L, and Patthy L (2015). Wnts grasp the WIF domain of Wnt Inhibitory Factor 1 at two distinct binding sites. *FEBS Lett.* 589, 3044–3051. [PubMed: 26342861]
- Kim GH, Her JH, and Han JK (2008). Ryk cooperates with Frizzled 7 to promote Wnt11-mediated endocytosis and is essential for *Xenopus laevis* convergent extension movements. *J. Cell Biol* 182, 1073–1082. [PubMed: 18809723]
- Konarev PV, Volkov VV, Sokolova AV, Koch MHJ, and Svergun DI (2003). PRIMUS: A Windows PC-based system for small-angle scattering data analysis. *J. Appl. Cryst* 36, 1277–1282.

- Kozin M, and Svergun DI (2001). Automated matching of high- and low-resolution structural models. *J. Appl. Cryst* 34, 33–41.
- Lahaye LL, Wouda RR, de Jong AW, Fradkin LG, and Noordermeer JN (2012). WNT5 interacts with the Ryk receptors doughnut and derailed to mediate muscle attachment site selection in *Drosophila melanogaster*. *PLoS One* 7, e32297. [PubMed: 22403643]
- Lemmon MA, and Schlessinger J (2010). Cell signaling by receptor tyrosine kinases. *Cell* 141, 1117–1134. [PubMed: 20602996]
- Lhoumeau AC, Puppo F, Prébet T, Kodjabachian L, and Borg JP (2011). PTK7: A cell polarity receptor with multiple facets. *Cell Cycle* 10, 1233–1236. [PubMed: 21415598]
- Li C, Chen H, Hu L, Xing Y, Sasaki T, Villosis MF, Li J, Nishita M, Minami Y, and Minoo P (2008). Ror2 modulates the canonical Wnt signaling in lung epithelial cells through cooperation with Fzd2. *BMC Mol. Biol* 9, 11. [PubMed: 18215320]
- Liebl FL, Wu Y, Featherstone DE, Noordermeer JN, Fradkin L, and Hing H (2008). Derailed regulates development of the *Drosophila* neuromuscular junction. *Dev. Neurobiol* 68, 152–165. [PubMed: 17963254]
- Liepinsh E, Banyai L, Patthy L, and Otting G (2006). NMR structure of the WIF domain of the human Wnt-inhibitory factor-1. *J. Mol. Biol* 357, 942–950. [PubMed: 16476441]
- Liu Y, Rubin B, Bodine PV, and Billiard J (2008). Wnt5a induces homodimerization and activation of Ror2 receptor tyrosine kinase. *J. Cell. Biochem* 105, 497–502. [PubMed: 18615587]
- Lu W, Yamamoto V, Ortega B, and Baltimore D (2004). Mammalian Ryk is a Wnt coreceptor required for stimulation of neurite outgrowth. *Cell* 119, 97–108. [PubMed: 15454084]
- MacDonald BT, and He X (2012). Frizzled and LRP5/6 receptors for Wnt/ β -catenin signaling. *Cold Spring Harb. Perspect. Biol* 4, a007880. [PubMed: 23209147]
- Malinauskas T (2008). Docking of fatty acids into the WIF domain of the human Wnt inhibitory factor-1. *Lipids* 43, 227–230. [PubMed: 18256869]
- Malinauskas T, Aricescu AR, Lu W, Siebold C, and Jones EY (2011). Modular mechanism of Wnt signaling inhibition by Wnt inhibitory factor 1. *Nat. Struct. Mol. Biol* 18, 886–893. [PubMed: 21743455]
- Mayne L, Kan ZY, Chetty PS, Ricciuti A, Walters BT, and Englander SW (2011). Many overlapping peptides for protein hydrogen exchange experiments by the fragment separation-mass spectrometry method. *J. Am. Soc. Mass Spectrom* 22, 1898–1905. [PubMed: 21952777]
- Mendrola JM, Shi F, Park JH, and Lemmon MA (2013). Receptor tyrosine kinases with intracellular pseudokinase domains. *Biochem. Soc. Trans* 41, 1029–1036. [PubMed: 23863174]
- Miao Y, Ha A, de Lau W, Yuki K, Santos AJM, You C, Geurts MH, Puschhof J, Pleguezuelos-Manzano C, Peng WC, et al. (2020). Next-generation surrogate Wnts support organoid growth and deconvolute Frizzled pleiotropy in vivo. *Cell Stem Cell* 27, 840–851. [PubMed: 32818433]
- Miller JR (2012). The Wnts. *Genome Biol* 3, REVIEWS3001.
- Nachtergaele S, Whalen DM, Mydock LK, Zhao Z, Malinauskas T, Krishnan K, Ingham PW, Covey DF, Siebold C, and Rohatgi R (2013). Structure and function of the Smoothed extracellular domain in vertebrate Hedgehog signaling. *eLife* 2, e01340. [PubMed: 24171105]
- Niehrs C (2012). The complex world of WNT receptor signalling. *Nat. Rev. Mol. Cell. Biol* 13, 767–779. [PubMed: 23151663]
- Nile AH, and Hannoush RN (2019). Fatty acid recognition in the Frizzled receptor family. *J. Biol. Chem* 294, 726–736. [PubMed: 30530496]
- Nile AH, Mukund S, Stanger K, Wang W, and Hannoush RN (2017). Unsaturated fatty acyl recognition by Frizzled receptors mediates dimerization upon Wnt ligand binding. *Proc. Natl. Acad. Sci. U. S. A* 114, 4147–4152. [PubMed: 28377511]
- Nishita M, Itsukushima S, Nomachi A, Endo M, Wang Z, Inaba D, Qiao S, Takada S, Kikuchi A, and Minami Y (2010). Ror2/Frizzled complex mediates Wnt5a-induced AP-1 activation by regulating Dishevelled polymerization. *Mol. Cell. Biol* 30, 3610–3619. [PubMed: 20457807]
- Nusse R, and Clevers H (2017). Wnt/ β -catenin signaling, disease, and emerging therapeutic modalities. *Cell* 169, 985–999. [PubMed: 28575679]

- Oishi I, Sugiyama S, Liu ZJ, Yamamura H, Nishida Y, and Minami Y (1997). A novel *Drosophila* receptor tyrosine kinase expressed specifically in the nervous system. Unique structural features and implication in developmental signaling. *J. Biol. Chem* 272, 11916–11923. [PubMed: 9115253]
- Oishi I, Suzuki H, Onishi N, Takada R, Kani S, Ohkawara B, Koshida I, Suzuki K, Yamada G, Schwabe GC, et al. (2003). The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling pathway. *Genes Cells* 8, 645–654. [PubMed: 12839624]
- Petersen J, Wright SC, Rodríguez D, Matricón P, Lahav N, Vromen A, Friedler A, Strömqvist J, Wennmalm S, Carlsson J, et al. (2017). Agonist-induced dimer dissociation as a macromolecular step in G protein-coupled receptor signaling. *Nat. Commun* 8, 226. [PubMed: 28790300]
- Petoukhov MV, Konarev PV, Kikhney AG, and Svergun DI (2007). ATSAS 2.1 - towards automated and web-supported small-angle scattering data analysis. *J. Appl. Cryst* 40, s223–s228.
- Petrova IM, Lahaye LL, Martiáñez T, de Jong AW, Malessy MJ, Verhaagen J, Noordermeer JN, and Fradkin LG (2013). Homodimerization of the Wnt receptor DERAILED recruits the Src family kinase SRC64B. *Mol. Cell. Biol* 33, 4116–4127. [PubMed: 23979591]
- Potter CJ, Tasic B, Russler EV, Liang L, and Luo L (2010). The Q system: a repressible binary system for transgene expression, lineage tracing, and mosaic analysis. *Cell* 141, 536–548. [PubMed: 20434990]
- Qi J, Li X, Peng H, Cook EM, Dadashian EL, Wiestner A, Park H, and Rader C (2018). Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1. *Proc. Natl. Acad. Sci. U. S. A* 115, E5467–E5476. [PubMed: 29844189]
- Reynaud E, Lahaye LL, Boulanger A, Petrova IM, Marquilly C, Flandre A, Martiane T, Privat M, Noordermeer JN, Fradkin LG, et al. (2015). Guidance of *Drosophila* mushroom body axons depends upon DRL-Wnt receptor cleavage in the brain dorsomedial lineage precursors. *Cell Rep* 11, 1293–1304. [PubMed: 25981040]
- Ripp C, Loth J, Petrova I, Linnemannstons K, Uleplic M, Fradkin L, Noordermeer J, and Wodarz A (2018). *Drosophila* Ror is a nervous system-specific co-receptor for Wnt ligands. *Biol. Open* 7, bio033001. [PubMed: 30341100]
- Roy JP, Halford MM, and Stacker SA (2018). The biochemistry, signalling and disease relevance of RYK and other WNT-binding receptor tyrosine kinases. *Growth Factors* 36, 15–40. [PubMed: 29806777]
- Russell J, Gennissen A, and Nusse R (1992). Isolation and expression of two novel Wnt/wingless gene homologues in *Drosophila*. *Development* 115, 475–485. [PubMed: 1425336]
- Sakurai M, Aoki T, Yoshikawa S, Santschi LA, Saito H, Endo K, Ishikawa K, Kimura K, Ito K, Thomas JB, et al. (2009). Differentially expressed Drl and Drl-2 play opposing roles in Wnt5 signaling during *Drosophila* olfactory system development. *J. Neurosci* 29, 4972–4980. [PubMed: 19369566]
- Schiefner A, and Skerra A (2015). The menagerie of human lipocalins: a natural protein scaffold for molecular recognition of physiological compounds. *Acc. Chem. Res* 48, 976–985. [PubMed: 25756749]
- Shihada H, Kowalski-Jahn M, Turku A, and Schulte G (2021). Deconvolution of WNT-induced Frizzled conformational dynamics with fluorescent biosensors. *Biosens Bioelectron.* 177, 112948. [PubMed: 33486136]
- Semenyuk AV, and Svergun DI (1991). GNOM - a program package for small-angle scattering data-processing. *J. Appl. Crystallogr* 24, 537–540.
- Sheetz JB, Mathea S, Karvonen H, Malhotra K, Chatterjee D, Niininen W, Perttila R, Preuss F, Suresh K, Stayrook SE, et al. (2020). Structural insights into pseudokinase domains of receptor tyrosine kinases. *Mol. Cell* 79, 390–405. [PubMed: 32619402]
- Speer KF, Sommer A, Tajer B, Mullins MC, Klein PS, and Lemmon MA (2019). Non-acylated Wnts can promote signaling. *Cell Rep* 26, 875–883. [PubMed: 30673610]
- Stiegler AL, Burden SJ, and Hubbard SR (2009). Crystal structure of the frizzled-like cysteine-rich domain of the receptor tyrosine kinase MuSK. *J. Mol. Biol* 393, 1–9. [PubMed: 19664639]
- Stricker S, Rauschenberger V, and Schambony A (2017). ROR-family receptor tyrosine kinases. *Curr. Top. Dev. Biol* 123, 105–142. [PubMed: 28236965]

- Tao Y, Mis M, Blazer L, Ustav M Jnr., Steinhart Z, Chidiac R, Kubarakos E, O'Brien S, Wang X, Jarvik N, et al. (2019). Tailored tetravalent antibodies potently and specifically activate Wnt/ Frizzled pathways in cells, organoids and mice. *Elife* 8, e46134. [PubMed: 31452509]
- Terwilliger TC, Dimaio F, Read RJ, Baker D, Bunkóczi G, Adams PD, Grosse-Kunstleve RW, Afonine PV, and Echols N (2012). Phenix.mr_rosetta: molecular replacement and model rebuilding with Phenix and Rosetta. *J. Struct. Funct. Genomics* 13, 81–90. [PubMed: 22418934]
- Tian W, Chen C, Lei X, Zhao J, and Liang J (2018). CASTp 3.0: computed atlas of surface topography of proteins. *Nucl. Acids Res* 46, W363–W367. [PubMed: 29860391]
- Tsutsumi N, Mukherjee S, Waghray D, Janda CY, Jude KM, Miao Y, Burg JS, Aduri NG, Kossiakoff AA, Gati C, et al. (2020). Structure of human Frizzled5 by fiducial-assisted cryo-EM supports a heterodimeric mechanism of canonical Wnt signaling. *Elife* 9, e58464. [PubMed: 32762848]
- Volkov VV, and Svergun DI (2003). Uniqueness of ab-initio shape determination in small-angle scattering. *J. Appl. Crystallogr* 36, 860–864.
- Wouda RR, Bansraj MR, de Jong AW, Noordermeer JN, and Fradkin LG (2008). Src family kinases are required for WNT5 signaling through the Derailed/RYK receptor in the *Drosophila* embryonic central nervous system. *Development* 135, 2277–2287. [PubMed: 18539923]
- Wright SC, Cañizal MCA, Benkel T, Simon K, Le Gouill C, Matricon P, Namkung Y, Lukasheva V, König GM, Laporte SA, et al. (2018). FZD₅ is a G α q-coupled receptor that exhibits the functional hallmarks of prototypical GPCRs. *Sci. Signal* 11, eaar5536. [PubMed: 30514810]
- Wu Y, Helt JC, Wexler E, Petrova IM, Noordermeer JN, Fradkin LG, and Hing H (2014). Wnt5 and drl/ryk gradients pattern the *Drosophila* olfactory dendritic map. *J. Neurosci* 34.
- Xu YK, and Nusse R (1998). The Frizzled CRD domain is conserved in diverse proteins including several receptor tyrosine kinases. *Curr. Biol* 8, R405–R406. [PubMed: 9637908]
- Yasunaga K, Tezuka A, Ishikawa N, Dairyo Y, Togashi K, Koizumi H, and Emoto K (2015). Adult *Drosophila* sensory neurons specify dendritic territories independently of dendritic contacts through the Wnt5-Drl signaling pathway. *Genes Dev.* 29, 1763–1775. [PubMed: 26302791]
- Ye Q, Rahman MN, Koschinsky ML, and Jia Z (2001). High-resolution crystal structure of apolipoprotein(a) kringle IV type 7: insights into ligand binding. *Protein Sci.* 10, 1124–1129. [PubMed: 11369850]
- Yoshikawa S, Bonkowsky JL, Kokel M, Shyn S, and Thomas JB (2001). The derailed guidance receptor does not require kinase activity in vivo. *J. Neurosci* 21, RC119. [PubMed: 11150355]
- Yoshikawa S, McKinnon RD, Kokel M, and Thomas JB (2003). Wnt-mediated axon guidance via the *Drosophila* Derailed receptor. *Nature* 422, 583–588. [PubMed: 12660735]




FIGURE 1. Structure of a ROR family ECR

(A) Domain composition of ROR and RYK/Drl family RTKs from *D. melanogaster* (left) and *H. sapiens* (right). The membrane is depicted as a horizontal gray bar. The pseudokinase domain is red, immunoglobulin-like domain blue, FZD-related CRD purple, Kringle domain grey, and WIF domain orange. Note that there are three RYK orthologs in *D. melanogaster*, but only one in humans.

(B) Cartoon representation of the sNr/s-dRor2 structure, with the CRD colored purple and Kringle domain grey. Secondary structure elements are labeled in the CRD only – using the designation introduced by the Leahy lab (Dann et al., 2001) – and the bound fatty acid molecule is shown as green and red spheres. Disulfides are shown as sticks, and the N-terminal hairpin is marked.

(C) Surface representation of sNr/s-dRor2, colored as in B. Note that burial of the bound fatty acid molecule causes it not to be visible at all in this representation.

See also Figure S1.




FIGURE 2. Comparison of ROR and FZD family CRDs and modes of fatty acid binding

(A) Cartoon representation of the sNrkr CRD in the same orientation as in Figure 1B, with secondary structure elements marked. Disulfide bonds are numbered (in gold) for the cysteine order, and the bound fatty acid is shown in spheres. The bend in helix α_4 that yields the C-terminal α_5 helix, is marked – as is the C-terminal region.

(B) Cartoon representation of the rat MuSK CRD (PDBID: 3HKL), in the same orientation used for Nrkr in A, and labeled similarly. Note the absence of bound lipid, but retention of the helix α_4 bend.

(C) Cartoon representation of the mouse FZD₈ CRD (PDBID: 1IJY), in the same orientation used for Nrkr in A, and labeled similarly. A bound palmitoleic acid is shown in green spheres based on its position in the xWnt8/mFZD₈ complex (PDBID: 4F0A).

(D) Unbiased $|F_o| - |F_c|$ Polder omit map, contoured at 3σ , of the region surrounding the palmitic acid binding site in the NrK CRD. The modeled fatty acid is shown in green sticks, and adjacent secondary structure elements and contacting side-chains are labeled. Note that the basic side-chains from K170, R179, and R183 ‘clamp’ the carboxylate of the fatty acid in position.

(E) NrK CRD shown with the same orientation used in **A**, but with the surface shown as transparent mesh. This representation reveals how the bound fatty acid is completely inaccessible from the domain’s surface – and thus completely buried. The $\alpha 5/C$ -terminal connector, which clamps the fatty acid in position, is colored red.

(F) Illustration of how the mFZD₈ CRD (cyan) engages the fatty acid attached to xWnt8. The acyl chain covalently attached to xWnt8 is depicted in green spheres (xWnt8 is grey), and lies in a surface channel formed between helices $\alpha 2$ and $\alpha 4$ (Janda et al., 2012) as described in the text.

(G) Binding of a free fatty acid (green spheres) to the mFZD₄ CRD (slate blue), shown in the same orientation as in **F**, from PDBID: 5UWG. As described (DeBruine et al., 2017), the same surface channel formed by helices $\alpha 2$ and $\alpha 4$ accommodates this acyl chain.

(H) Fatty acid binding to the NrK CRD, shown in the same orientation as in **F** and **G**, illustrating that the position of the fatty acid binding site is very different. The bound fatty acid is fully buried, and CRD structural changes occlude the channel between $\alpha 2$ and $\alpha 4$ as described in the text.

See also Figure S2.




FIGURE 3. RYK family WIF domain structure and comparison with WIF-1

(A) Structure of the complete Drl-2 ECR (colored orange) in cartoon representation, shown in two orthogonal views. Secondary structure elements are marked – using the designation introduced by Liepinsh et al. (2006). The WIF domain ends around residue 161 (see Figure S3), and the remainder of the ECR (aa 162–182) is involved in crystal packing.

(B) Cartoon view of the WIF domain from human WIF-1 (PDBID: 2YGN), overlaid and shown in the same orientations as in A (Malinauskas et al., 2011). The WIF domain is colored deep teal, and the bound DPPC molecule is shown as black spheres (red and orange for phosphates). The two regions described as inserts in the WIF-1 WIF domain (a 3_{10} helix and insert in $\beta 9$) compared with that in Drl-2 are colored magenta.

(C) Closer view of the hydrophobic core of the Drl-2 WIF domain, using the same orientation as the right-hand side of A, showing that it is well packed, with no cavity capable of accommodating a lipid molecule.

(D) Overlay of the Drl-2 and WIF-1 WIF domains in two halves as described in the text. The half of the sandwich including $\beta 1$, $\beta 2$, $\beta 4$, $\beta 7$, and $\alpha 1$ overlays very well. The other half shows more deviations, particularly around $\alpha 2$ (where the magenta insert forms a 3_{10} helix) and in $\beta 9$ (where a magenta loop/bulge is seen). These changes allow DPPC to bind WIF-1's WIF domain, whereas the longer (and straight) $\beta 9$ – along with $\beta 3$ – occludes the potential lipid-binding site in Drl-2 (and likely other RYK family members).

See also Figure S3.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




FIGURE 4. Binding of WNTs to ROR and RYK/Drl family ECRs

(A) Pull-down experiment (see Method Details), showing that histidine-tagged sDrl₁₈₃ and sDrl₂₄₂ bind robustly to DWnt-5 in solution when precipitated with Ni-NTA beads and analyzed by immunoblotting with anti-DWnt-5. The dRor ECR (s-dRor) binds less robustly, and sNrK still more weakly. Lack of binding to the PTK7 ECR is shown as a control. Data are representative of at least 3 biological repeats.

(B) Pull-down experiment showing that the histidine-tagged hROR2 ECR similarly precipitates mWNT-5a weakly from conditioned medium from Expi293 cells expressing it. Neither the hROR1 ECR nor a human EGFR ECR control precipitate mWNT-5a in parallel experiments. Note the lack of effect of a mWNT-5a acylation site (S244A) mutation, as discussed in the text. Data are representative of at least 4 biological repeats. The poor

resolution of the anti-WNT-5a blot image reflects use of X and Y pixel binning to increase sensitivity and detect the weak luminescence signal.

(C) Representative Coomassie-stained SDS-PAGE gel of purified DWnt-5, run after size-exclusion chromatography.

(D) MS/MS product ion spectrum of 4+ charged ion at m/z 821.4, corresponding to the non-acylated peptide containing S868 of purified DWnt-5, the putative acylation site of this WNT ortholog. The ability to see this peptide at this abundance, alongside the monomeric behavior of DWnt-5, argues that it is not acylated.

(E) SPR studies of Drl family ECRs binding to DWnt-5 immobilized on a sensorchip. Fit K_D values from at least 3 biological repeats are quoted \pm standard deviation (SD).

(F) Corresponding reverse SPR experiment, with DWnt-5 (in solution) binding to immobilized sDrl, sDrl-2 and sDnt. Fit K_D values from at least 3 biological repeats are quoted \pm standard deviation (SD).

See also Figure S4.




FIGURE 5. Locating the DWnt-5/Drl binding interface

(A) Pull-down experiments indicate that DWnt-5 does not cause sDrl₂₄₂ dimerization. FLAG-tagged and V5-tagged versions of sDrl₂₄₂ were incubated with DWnt-5 (see Method Details) and immunoprecipitated with anti-FLAG. The quantity of V5-sDrl immunoprecipitated was not increased by the presence of FLAG-sDrl with- or without DWnt-5, arguing that they do not form dimers on WNT binding. Representative result from at least 3 independent experiments.

(B) SPR data showing that Y52E, F56E, and V58E mutations (magenta) in sDrl₂₄₂ greatly impair binding to immobilized DWnt-5. An E40K mutation (tan) has an intermediate effect, whereas E126K or I154E mutations (green) have no detectable effect. Representative binding curves from at least 2 biological repeats are shown.

(C) Surface representation of the sDrl WIF domain model (based on the sDrl-2 WIF domain structure described here), showing the location of the mutations studied in B.

(D) Cartoon of sDrl model, colored by the change in ‘weighted relative difference’ in hydrogen/deuterium exchange (HDX) at the 1,000 s time point upon DWnt-5 binding (see Method Details). Regions in β1, α1, β2, α2 and to some extent β8 show some protection. Side-chains of residues mutated in B are marked and colored as in B.

(E) Limited HDX study of DWnt-5 changes upon binding sDrl in the same experiment. As described in the text, the large number of disulfides limit peptide coverage in DWnt-5. Grey/white areas are not seen in the recovered peptides. Only regions colored black were seen among the peptides (<50%), but none showed significant changes in HDX except the region colored red: A920-D927 in this threaded (xWnt8-based) model (Kelley et al., 2015) of DWnt-5.

See also Figure S5.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




FIGURE 6. A DWnt-5 binding-deficient Drl variant abolishes commissure switching in vivo (A) Schematic depiction of the Eg-Gal4 xUAS-Drl assay. One set of Eg⁺ neurons (blue) crosses the ventral midline via the posterior commissure (PC), and the other (magenta) through the anterior commissure (AC). DWnt-5 (green) is expressed predominantly by neurons that pass through the PC, which normally do not express Drl. When wild-type Drl is expressed ectopically in the Eg⁺ lineage, neurons that normally cross in the PC switch to cross in the AC, just below, to avoid the repulsive DWnt-5 signal. PC-to-AC switching of the Eg⁺ neurons therefore represents an assay for wild-type Drl function (Fradkin et al., 2004; Petrova et al., 2013; Yoshikawa et al., 2003). The penetrance of this phenotype is dependent on the levels of wild-type Drl expression; high levels result in essentially complete switching in all segments. We previously generated a Eg-GAL4/UAS-Drl line that serves as sensitized

background. Individuals bearing single copies of the driver and the UAS-Drl insert display little commissure switching, whereas those with two copies display significantly increased levels of switching (Petrova et al., 2013).

(B) Representative photographs of embryonic ventral nerve cords expressing wild-type (left) versus F56E-mutated (right) Drl in the single-copy sensitized background. Commissure switching occurred in wild-type Drl-expressing cases (2 of 3 commissures shown) but not in the F56E-expressing background.

(C) Scoring of commissure switching in controls, and embryos expressing wild-type Drl versus F56E-mutated Drl in the sensitized background. All animals, including the sensitized background control, contain single copies of the Eg-GAL4 transgene and a MYC-tagged wild-type DRL UAS transgene. The GFP control, wild-type, and F56E mutated transgenes are all present as a single copy. Expression of wild-type Drl results in robust commissure switching, whereas F56E-mutated Drl supports switching only at low background levels. At least 400 hemisegments were scored for each genotype, and *n* values are listed above the relevant bar.

See also Figure S6.

TABLE 1.

Crystallization Conditions, Data Collection, and Refinement Statistics

| Protein | sNr/s-dRor2 | sDr1-2 |
|--|---|--|
| PBD ID | 7ME4 | 7ME5 |
| Crystallization Conditions | 3 mg/ml protein, 50 mM Bis-Tris propane (pH 5.0), 20% PEG 3350, 21 °C | 12 mg/ml protein, 100 mM Tris (pH 8.5), 100 mM sodium acetate, 25% PEG 6000, 15% glycerol, 21 °C |
| Data Collection ^a | | |
| Source | APS 24-ID-E | Rigaku 007HF |
| Wavelength (Å) | 0.9792 | 1.5418 |
| Space Group | C2 | C222 ₁ |
| Cell Dimensions | | |
| a, b, c (Å) | 95.70, 74.69, 61.55 | 56.97, 91.58, 76.36 |
| α, β, γ (°) | 90, 106.31, 90 | 90, 90, 90 |
| Resolution (Å) | 45.61 – 1.75 | 50.00 – 2.0 |
| Completeness (%) | 88.5 (78.0) | 99.53 (94.2) |
| Redundancy | 2.2 (1.8) | 6.6 (3.6) |
| R _{sym} | 0.046 (0.744) | 0.061 (0.769) |
| I/ σ | 9.1 (1.0) | 19.1 (1.5) |
| CC ^{1/2} | 0.998 (0.630) | 0.999 (0.597) |
| Refinement | | |
| Number of reflections | 36,909 | 13,749 |
| R _{work} /R _{free} (%) | 19.9/22.2 | 21.8/24.8 |
| Number of atoms | | |
| Protein | 1,833 | 1,209 |
| Ligands | 18 | - |
| Carbohydrate | 28 | 14 |
| Water | 275 | 84 |
| Average B factor (Å) | | |
| Protein | 41.95 | 25.26 |
| Ligands | 75.53 | - |
| Carbohydrates | 63.49 | 90.50 |
| Water | 49.26 | 52.30 |
| Ramachandran favored (%) | 97.7 | 99.3 |
| Ramachandran allowed (%) | 2.3 | 0.7 |
| Ramachandran outliers (%) | 0 | 0 |
| Bond length rmsd (Å) | 0.009 | 0.006 |
| Bond angle rmsd (Å) | 0.950 | 0.784 |

Numbers in parentheses denote highest resolution shell

KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|---------------------------|-----------------------------------|
| Antibodies | | |
| Mouse Anti-6xHis monoclonal, clone 6AT18 | Sigma | Cat#: SAB1305538; RRID:AB_2687993 |
| Rabbit Anti-Wnt-5a monoclonal | Cell Signaling Technology | Cat#: 2530; RRID:AB_2215595 |
| Rabbit Anti-FLAG monoclonal | Cell Signaling Technology | Cat#: 14793; RRID:AB_2572291 |
| Mouse Anti-V5 monoclonal | Sigma | Cat#: V8012; RRID:AB_261888 |
| Rabbit Anti-DWnt-5 polyclonal | (Fradkin et al., 1995) | N/A |
| Goat Anti-mouse IgG monoclonal, HRP, secondary | ThermoFisher Scientific | Cat#: 62-6520; RRID:AB_2533947 |
| Goat Anti-rabbit IgG monoclonal, HRP, secondary | ThermoFisher Scientific | Cat#: 65-6120; RRID:AB_2533967 |
| Rabbit Myc Tag polyclonal | ThermoFisher Scientific | Cat#: PA1-981; RRID:AB_325961 |
| Chemicals, Peptides, and Recombinant Proteins | | |
| cOmplete, mini, EDTA-free Protease Inhibitor Cocktail | Sigma-Aldrich/Roche | Cat#: 11836170001 |
| Recombinant PNGaseF enzyme | New England Biolabs | Cat#: P0704S |
| Deuterium Oxide (99.9%) Low paramagnetic | Cambridge Isotope Labs | Cat#: DLM-11-100 |
| Ni-NTA Agarose Beads | Qiagen | Cat#: 30210 |
| Pierce ECL Western Blotting Substrate | ThermoFisher Scientific | Cat#: 32106 |
| 3,3'-diaminobenzidine (DAB) | Sigma-Aldrich/Roche | Cat#: D8001 |
| Gateway LR Clonase II Enzyme Mix | ThermoFisher Scientific | Cat#: 11791020 |
| Deposited Data | | |
| sNrk/s-dRor2 crystal structure | This study | PDBID: 7ME4 |
| sDrl-2 crystal structure | This study | PDBID: 7ME5 |
| Experimental Models: Cell Lines | | |
| Insect: <i>S. frugiperda</i> Sf9 cells | Expression Systems | Cat#: 94-001F; RRID: CVCL_0549 |
| Insect: <i>T. ni</i> BTI-Tn-5B1-4 cells | Expression Systems | Cat#: 94-002F; RRID: CVCL_C190 |
| Insect: <i>D. melanogaster</i> S2 cells | ThermoFisher Scientific | Cat#: R69007; RRID: CVCL_Z232 |
| Human: Expi293™ cells and expression system | ThermoFisher Scientific | Cat#: A14635; RRID: CVCL_D615 |
| Recombinant DNA | | |
| pUAST-DWnt-5 | (Fradkin et al., 2004) | N/A |
| pUAST-DWnt-5 _{insert} | (Fradkin et al., 2004) | N/A |
| pAc-Gal4 | (Potter et al., 2010) | RRID:Addgene_24344 |
| pCoHygro | ThermoFisher Scientific | N/A |
| pcDNA mWnt-5a | (Speer et al., 2019) | N/A |
| pcDNA mWnt-5a S244A | (Speer et al., 2019) | N/A |
| pFastbac1 sEGFR | (Ferguson et al., 2003) | N/A |
| pFastbac1 sDrl ₂₄₂ | This study | N/A |
| pFastbac1 sDrl ₁₈₃ | This study | N/A |

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|--------------------------------------|--|---|
| pFastbac1 sDrl E40K | This study | N/A |
| pFastbac1 sDrl Y52E | This study | N/A |
| pFastbac1 sDrl F56E | This study | N/A |
| pFastbac1 sDrl V58E | This study | N/A |
| pFastbac1 sDrl E126K | This study | N/A |
| pFastbac1 sDrl I154E | This study | N/A |
| pFastbac1 sDrl-2 | This study | N/A |
| pFastbac1 sDnt | This study | N/A |
| pFastbac1 s-hROR1 | This study | N/A |
| pFastbac1 s-hROR2 | This study | N/A |
| pFastbac1 sNrk | This study | N/A |
| Baculovirus shuttle vector bMON14272 | ThermoFisher Scientific | Cat #: 10359-016 |
| Software and Algorithms | | |
| GraphPad Prism 7 | GraphPad Software, La Jolla California USA | https://www.graphpad.com/scientific-software/prism/ |
| Scaffold version 5 | Proteome Software, Inc. | https://www.proteomesoftware.com/products/scaffold-5 |
| Coot | (Emsley and Cowtan, 2004) | http://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot |
| CCP4i | (CCP4, 1994) | http://www.ccp4.ac.uk/download/index.php |
| PyMol | Schrödinger | www.pymol.org |
| PHENIX | (Adams et al., 2010) | https://www.phenix-online.org |
| SEQUEST version 3.3.1 | Bioworks, Inc. | http://tools.thermofisher.com/content/sfs/manuals/Man-XCALI-97194-BioWorks-331-SP1-User-ManXCALI97194-B-EN.pdf |
| ExMS | (Kan et al., 2011) | N/A |
| Matplotlib | (Hunter, 2007) | https://matplotlib.org/ |
| RStudio | RStudio, Inc. | https://www.rstudio.com/ |